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IMPACT OF ACTIVATED AND RESTING MESENCHYMAL STEM CELLS ON IMMUNE 
RESPONSES AND GUT MICROBIOME AND IMMUNE RESPONSES TO GUT BACTERIA 
IN DOGS WITH INFLAMMATORY BOWEL DISEASE 
 
 
Idiopathic inflammatory bowel disease (IBD) is one of the common diseases that causes 
gastrointestinal tract (GI) disorder and encompasses a group of unknown causes of chronic 
gastroenteropathies found to have persistent or recurrent GI signs along with intestinal and/or 
gastric inflammation. Similar to IBD in humans, the pathogenesis of IBD in dogs remains 
undiscovered, but it is believed to involve an interaction between the abnormal host immune 
response against intestinal microbiota and predisposing genetic and environmental factors. IBD is 
mostly incurable with long-term complications despite receiving standard treatments that are 
typical combinations of food trial, antibiotics, anti-inflammatory and immunosuppressive drugs. 
However, the therapeutic outcome of medical treatment appears to be multifactorial and 
inconsistent therapeutic responses ranging from transient recovery to no response have been found. 
One of the alternative treatments that potentially accelerates therapeutic effects is the use of 
mesenchymal stem cell (MSC) administration. Therefore, the goal of the research presented in this 
dissertation was to comprehensively investigate the impact of activated and resting MSCs on 
immune responses, cells regeneration and gut microbiome for treatment of IBD with a specific 
emphasis on gaining an improved understanding of the immune responses to the gut bacteria in 
dogs with IBD. 
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In the first part of the study, we needed to have better understanding of 
immunopathogenesis in IBD. Although it is not clear what triggers the intestinal inflammations in 
IBD affected dogs, we hypothesized that the disease may be mediated, in part, by an abnormal 
immune response directed against intestinal bacteria. We found the substantially greater 
percentages and overall binding of IgG and IgA with their intestinal bacteria in IBD dogs than 
healthy dogs, and the primary production of anti-bacterial antibodies occurs locally in the gut 
rather than systemically. The IgG-binding bacteria triggered an increase of phagocytosis and pro-
inflammatory cytokine production by macrophages. Moreover, Actinobacteria (Collinsella genus) 
was the preferential target for the mucosal IgG immune response to dysbiotic bacteria. We 
concluded that the mucosal antibody binding to commensal gut bacteria was substantially greater 
in dog with IBD compared to a healthy, and that the immune response targeted particular bacteria 
and triggered the pro-inflammatory response in IBD. We noted that the more extensive studies in 
dogs with IBD and compared to animals with other causes for GI dysfunction may be required.  
Then, we focused on the use of MSCs as an alternative treatment for IBD in animals and 
humans. To address this question, we used a mouse model of IBD to investigate the effectiveness 
of using 2 types of mesenchymal stem cells (induced pluripotent MSC [iMSC] and conventional 
adipose-derived MSC [adMSC]) for the treatment of IBD. The impact of MSCs on immune 
responses, cells regeneration and the gut microbiome were evaluated. We found that iMSC and 
adMSC treatment effects were equivalent on the basis of significantly improving clinical 
abnormalities and decreasing inflammation inside the gut.  Both types of MSC also stimulated a 
significant increase in intestinal epithelial cell proliferation and amplified intestinal angiogenesis. 
Furthermore, the abnormal microbiome found in mice with IBD was returned to nearly normal 
values in terms of complexity and composition in mice with IBD treated with adMSC or iMSC. 
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We concluded therefore that the administration of iMSC enhanced the overall intestinal healing, 
suppressed inflammation, and microbiome restoration with equal effectiveness as treatment using 
adMSC in a mouse model of IBD. The future studies in animal model including spontaneous IBD 
in dog or large scale of clinical trial for long-term follow-up to determine iMSC safety and efficacy 
is required before clinical translation. 
Finally, we investigated possible ways to improve the efficacy of mouse and dog MSC 
treatment by preactivating the MSC with inflammatory cytokines (IFN-g or TNF-a) or TLR 
agonists (TLR3 or TLR9 agonists). We investigated the response of canine MSCs to the 4 
activating stimuli, including measurement of cell surface phenotype and cytokine release.  
Contrary to previous studies in other species including mouse and man, we found that the pre-
activation of dog MSC generally had little effect on either phenotype or function.  Therefore, we 
concluded that the ex-vivo preactivation of canine MSCs by inflammatory cytokines or TLR 
agonists is not warranted in terms of augmenting the functionality of the cells.  We further 
concluded that dog MSC may be hyporesponsive to preactivating stimuli compared to those of 
MSC from other species such as mouse and man.  Further studies are required for better 
understanding of the biology of canine MSCs and their responses to immune activation. 
Overall, the work described in this dissertation has increased our understanding regarding 
the immunopathogenesis of the IBD in dogs.  The studies have also demonstrated the equivalent 
activity of iMSC and conventional adMSC for treatment of IBD, and also documented a previously 
undescribed restorative effect of MSC on the intestinal microbiome.  These studies also illustrated 
species specific differences in the responsiveness of MSC to common immune stimuli. These 
studies provide a robust foundation for further research and hopefully this work can help stimulate 
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1.1 Overview of Canine Inflammatory Bowel Disease (IBD) 
 
1.1.1 Pathophysiology and Etiology 
 
1.1.1.2 Demographic and Disease Characteristic of IBD in Dogs 
Idiopathic inflammatory bowel disease (IBD) is one of the common diseases that causes 
gastrointestinal tract (GI) disorder and encompasses a group of unknown causes of chronic 
gastroenteropathies found to have persistent or recurrent GI signs along with intestinal and/or 
gastric inflammation 1-4. Treatment with food trials, antibiotics or immunosuppressive drugs 
results in various therapeutic responses of transient recovery, including no response 1, 3, 5. The 
pathogenesis of IBD in dogs remains poorly understood, but based on analogy to IBD in humans, 
is believed to involve an interaction between the abnormal host immune response against intestinal 
microbiota and predisposing genetic and environmental factors 6-9. The primary features of IBD in 
dogs mostly resemble those in humans 4, 10, including high genetic sequence similarity 11 and 
pathogenesis 12, as well as the need for clinical intervention2, 13. Thus, spontaneous IBD in dog is 
considered a potential model for study, with the potential for extrapolation to human IBD. 
The etiology of IBD in dogs remains mostly unknown. This disease has some features 
similar to other GI diseases that have known causative agents, including GI infectious diseases 2. 
Additionally, IBD in dogs affects both genders equivalently and mostly is found in middle-aged 
dogs 14. Although, several breeds have been documented to have a susceptible gene linked to 
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intestinal inflammation 11, 14, 15. IBD potentially develops in most breeds, as it is a multifactorial 
disease. Exposure to other potential factors may also trigger the disease 6-9.      
In human with Crohn’s Disease (CD) and Ulcerative Colitis (UC), disease-susceptible 
genes have been recognized, and mutations have been investigated in particular genes 12, 16-18. The 
recent studies in human and genetically engineered animals have documented that abnormal host 
immune response is potentially influenced by predisposed genes of IBD, including 
NOD2/CARD15, IBD5, IL23R, and IRGM, as well as single nucleotide polymorphisms (SNPs)16, 
19-21. A previous study reported that the German Shepherd dog breed (GSD) has been found to 
have 16 susceptible genes linked with IBD, such as Tlr5, IL13 and IL4 11, 15. Some of these genes 
have been noted to play a role in Th2 pathway cytokines and are involved in UC pathogenesis in 
humans 18, 22. In addition, several dog breeds, for example, Basenji and Boxer, are predisposed to 
specific types of IBD ; however, recent evidence has shown that Granulomatous Colitis in Boxer 
is associated with invasive E. coli in the gut mucosa 23.  Overall, dog IBD mostly resembles human 
IBD, and it is a multifactorial disease with unclear etiology. Dysbiosis 24, environmental factors 
and genetics 2, 11 are associated a dysregulated immune system, leading to intestinal injury 
(described in a later part). 
 
 1.1.1.3 Dysregulated Host Immune Response (Innate, Cell-Mediated and Humoral Immunity)  
Abnormal innate immunity has a critical role and has long been associated with IBD 
development 12, 25. Previous studies have reported an increased upregulation of Toll-like receptors 
(TLRs) and a higher presence of NF-kB activation, along with alteration of enteric immunity in a 
tissue biopsy from an IBD dog 15, 26-32. TLRs on the surface of intestinal epithelial cells are thought 
to be crucial to maintaining intestinal mucosal tolerance to luminal bacteria 33, 34, and these TLRs, 
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including TLR2, TLR4, TLR5, and TLR9, were found to upregulate diseased tissues 15, 26. Genetic 
abnormalities, including innate allelic variation and polymorphisms of those TLRs are thought to 
cause a functionally abnormal response to intestinal microbiota 12, 15. Moreover, the degree of TLR 
expression in the duodenal tissue from IBD dogs was correlated to the disease activity index 28. 
Uncontrolled or inappropriate TLRs activation and the subsequent loss of gut flora homeostasis 
can lead to the induction of an adaptive immune response and development of inflammation by 
pro-inflammatory cytokine production 28, 32, 33, 35. 
Another significant innate immunity defect in IBD is NOD2, which is expressed in Paneth 
cells, dendritic cells (DC), macrophages and absorptive intestinal epithelial cell (IECs) 20. NOD2 
senses the bacterial lipopolysaccharide and activates downstream pathways, including NF-kB 21 
and mitogen-activated protein kinase (MAPK), leading to the generation of an immune response 
16. Some studies have identified mutations in the NOD2 gene as relevant to CD pathogenesis 16, 19, 
21. Additionally, multiple SNPs were documented in the NOD2 gene found in IBD-affected GSD 
other breeds, suggesting that NOD2 mutations play an essential role in developing chronic mucosal 
inflammation in a canine population 36. Thus, the impaired innate immune system contributes to 
the defective mucosal barrier and abnormal bacterial defense, contributing to inflammation of gut 
mucosa. 
   Dysregulated cell-mediated immune responses contributing to IBD pathogenesis have 
been reported in human IBD, including abnormal T cell activity; reduced regulatory T cells; 
abnormal bacterial killing activity; and increased activity of macrophages, lymphocytes, and 
neutrophils in gut mucosa 37-39. Similar to observations made in humans, studies in dogs with IBD 
have shown an increase in specific immune cell infiltration, including IgA+ and IgG+ plasma cells, 
CD3+, CD4+, and CD8+T cells, macrophages, DC and neutrophils in the affected tissue 27, 31, 40, 
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41. CD4+ T cells are considered to play a key role in disease pathogenesis of IBD by regulating the 
Th1/Th2 pathway activation. These Th cells exert their effects by secreting proinflammatory (Th1 
[IL-2, IL-12, IFN-g, and TNF-a], Th2 [IL-4, IL-5 and IL-6]) or immunomodulatory cytokines (IL-
10 and TGF-b) 12, 22, 41-44. Additionally, previous studies in human and experimental colitis have 
reported that Th17 cells are potentially involved in the pathogenesis of IBD 42. The activation of 
the Th17 pathway results in pro-inflammatory cytokine (IL-17) production with subsequently 
tissue inflammation37, 45, 46. In addition, intestinal macrophages 47, 48, as well as DC 41, 49, 50, play a 
crucial role in maintaining homeostasis and regulating inflammation 51. One of their functions is 
to keep the balance between the immune tolerance to gut flora and mucosal inflammation by 
balancing the regulatory T cell number and IL-10 production 41-43, 45, 52-55. Dysregulation of these 
immune cells, which are associated with an increase in pro-inflammatory stimulation and less 
counterbalanced regulatory T cells, is generally believed to lead to the development of IBD 22, 37, 
41, 43, 47, 50. On the other hand, a reduction in some inflammatory cells, such as activated macrophage 
and T helper cells, is associated with clinical improvement in dogs with IBD; however, the CD3+ 
T cell was unchanged after clinical remission 13, suggesting that mucosal specific adaptive 
immunity may reside for a long period in the affected tissue 22, 42, 47. 
In dogs with IBD, the mucosal cytokine profiles are defined broadly as being mixed, 
resembling the Th1/Th2 cytokine activation observed in human IBD and experimental colitis 22, 42, 
56, 57. A significant amount of pro-inflammatory cytokines has been reported in CD (described 
previously). In dogs, increased IL-1B, IL-2, IL-5, IL-12p40, TNF-a and TGF-b have been observed 
in the mucosal tissue of a dog with IBD 27, 29, 30, 58, 59. However, similar changes also have been 
observed in gut inflammation due to Small Intestinal Bacterial Overgrowth (SIBO), suggesting a 
nonspecific cytokine profile for dog IBD 58. The reasons behind this could be the variation that 
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occurs in the cytokine profiles over time in the different stages of disease 30. In addition, TGF-b 
and IL-2 are potent immunoregulatory cytokines within the intestinal mucosa, and an increased 
level in these cytokines may suggest an attempt to downregulate an ongoing inflammatory 
response; however, no significant change was reported for IL-10 in several dog studies 30, 58. 
In IBD, excessive humoral immune (HI) response also plays a crucial role in the induction 
of chronic active mucosal inflammation60-67. The augmented HI response against commensal gut 
bacteria by increased Immunoglobulin (Ig) binding to gut bacteria was observed in both systemic 
and local responses in human IBD 63, 65, 67. In dogs with IBD, increased IgG +ve plasma cells at 
the lamina propria and increased concentrations of IgG in supernatant samples of colonic lavage 
indicate an immune activation 27, 64. Moreover, IBD dogs had significantly higher levels of IgG 
and IgA bound to gut bacteria than healthy controls, and these antibodies were primarily produced 
locally in the gut rather than systemically (Soontararak, et.al manuscript submitted). Moreover, Ig-
binding bacteria enhanced a proinflammatory effect by increased macrophage phagocytosis and 
activation, causing elevated TNF-a. This interaction could explain the presence of their commensal 
bacteria within mucosal macrophage of IBD dogs and remission signs after receiving 
immunosuppressive drug intervention41, 68. Overall, the predisposing genetic and environmental 
factors that contributed to an abnormal phenotype and impaired function of the mucosal immunity 
and abnormal host immune response against intestinal microbiota are considered the critical reason 
for the development of IBD. 
 
1.1.2 Presenting Signs and Diagnosis 
Common presenting signs in dogs are signs of chronic or relapsing gastrointestinal upset 
including vomit, diarrhea, weight loss, and alteration of appetite 2, 13, 69. The clinical manifestations 
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of IBD may be diverse, depending on the organ(s) involved, the presentation of active/inactive 
disease, severity of inflammation and physiologic complications, including protein loss and 
malnutrition2, 3, 70, 71. The duration of sickness is more than 3 weeks, with recovery typically 
involving treatment with antibiotics, diets and/or immunosuppressants; however, many cases 
relapse or do not respond 3, 5, 72. The lesion may involve any portion of the GI tract, including the 
stomach, small intestine and/or colon. Disease affecting the stomach and duodenum is associated 
with vomiting and small bowel diarrhea, whereas colonic involvement shows signs of large bowel 
diarrhea, including mucoid/bloody diarrhea with tenesmus 2, 28, 30. The extensive lesion along the 
GI tract results in mixed bowel diarrhea. Importantly, other diseases also mimic IBD symptoms 
and would be considered for IBD differential diagnosis including food responsive diarrhea (FRD) 
and antibiotic-responsive diarrhea (ARD) 13, 73. Additionally, the patient does not experience a full 
recovery with dietary and antibiotic treatment trial and typically needs immunosuppressants or 
anti-inflammatory therapy 5, 72, 74, 75. Therefore, the diagnosis of IBD is likely challenging and 
requires comprehensive diagnostic tests to rule out other known causes of GI inflammatory 
disorder. 
Several diagnostic tests are necessary to rule out other primary GI diseases because no 
specific diagnostic test nor pathognomonic marker exists to identify the IBD 69, 76-78. Not only IBD, 
but other diseases causing GI signs and intestinal inflammation are in the differential lists, and 
these include parasitic, bacterial infection, non-GI disorder, exocrine pancreatic insufficiency, and 
SIBO 78-81. Fecal examination by wet mount, fecal floatation and IFA are useful for parasitic 
infection 82. Fecal culture testing for pathogenic bacteria may be done in the suspicions exist of 
pathogenic bacterial infection. Routine hematology possibly will reveal systemic inflammation, 
including neutrophilia with or without left shift. Biochemical analysis may reveal the abnormality 
7 
 
of other organs related to GI signs and patient health assessment including hypoalbuminemia and 
hyperglobulinemia in dog with protein-losing enteropathy (PLE), which is associated with a 
negative outcome 71, 73. In many cases of chronic small bowel disease, serum cobalamin is reduced 
due to cobalamin malabsorption, and this may cause delayed recovery time and poor prognosis 71. 
Abdominal ultrasound is useful for defining the affected area of mucosal disease, including wall 
thickening, diffused lesion to deeper tissue, or presence of lymphadenopathy and prompt fine 
needle aspiration for cytology 83. 
Endoscopic examination with mucosal biopsy is crucial to confirm the gut mucosal 
inflammation. Mucosal friability increases granularity, and erosion is reported as an abnormality 
seen in dog IBD 84, 85 , and the extensive lesion may presence along both duodenal and colonic 
section 84, 86. However, a study on dogs with severe clinical illness measured by CIBDAI did not 
show a correlation to endoscopic score 71.  
Histopathologic evaluation of biopsy samples is required for definitive diagnosis of 
intestinal inflammation 87-89. Although the histopathologic changes may be found in any GI 
segment, the small intestine is commonly the predominately affected site 89. According to WSAVA 
guidelines for histopathologic evaluation for gastrointestinal inflammation 87, microscopic 
findings for dog IBD are classified based on the cellular infiltration within the intestinal mucosa 
and the varying degree of morphologic or cytoarchitectural damage accompanying this infiltration 
77. Although infiltration of inflammatory cells, including lymphocytes, neutrophils, eosinophils, 
and macrophages, can be found, lymphocytic-plasmacytic enteritis is the most common finding in 
dog with IBD 73. Additional techniques, including special stain and fluorescence in situ 
hybridization (FISH), are considered if neutrophils or macrophages increase with a suspicious 
infectious process 82.   
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Similar to the approach used in humans, several clinical parameters are currently used in 
dogs as potential markers for diagnosis and patient assessment in chronic gastroenteropathy4, 25, 90-
93. Clinical indices utilize a scoring system evaluated from GI signs alone (CIBDAI) 3 or are 
incorporated with clinical laboratory testing (CCECAI) 71, and these approaches remain the most 
widely used tools in the evaluation of disease activity in dog IBD. Because evaluation using disease 
activity index alone might have limitations, other biomarkers are used in human IBD to identify 
low-grade inflammation, response to treatment, remission, and relapsing for preemptive 
treatment91, 94-96. Fortunately, some of the human biomarkers are available in dog; however, those 
biomarkers have shown inconsistent results reports in several dog IBD studies 25, 90, 92, 97. A variety 
of noninvasive serologic markers including anti-neutrophil cytoplasmic antibodies (pANCA), 
matrix metalloproteinases (MMPs), TNF-a, and IL-6 90, 93, 98 provide an indirect assessment of 
disease activity and found the lack or weak correlation to the disease activity index, and endoscopic 
and histopathologic assessments in dog with IBD 86, 98. Serum C-reactive protein (CRP)92 and fecal 
calprotectin 25, 92, 99 were reported to be useful in assessing the response to treatment. However, 
serum CRP did not show a significant correlation with the CIBDAI and histopathologic lesion 
score 92. So far, fecal calprotectin is suggested as a useful candidate biomarker that shows a 
significant positive correlation to other clinical parameters for dog IBD 92. In summary, a diagnosis 
for IBD requires multiple diagnostic tools and likely needs diet and/or antibiotic therapy trials to 
rule out other known causes of GI inflammation. Idiopathic IBD is applied to dogs with intestinal 
inflammation confirmed by histological evaluation and that shows an inadequate response to 
dietary and antibiotic treatment trials. Additionally, no gold standard tool or biomarker is 
ultimately used for IBD diagnosis. These markers are beneficial for clinician use as adjunctive 




1.1.3 Therapeutic Management and Prognosis 
Treatment principles for canine IBD involve combination therapy using dietary and 
pharmacologic interventions 5, 72, 73, 100. Although, limited studies with randomized, controlled drug 
trials have been performed on dogs with IBD, evidence-based observations have shown that 
feeding an elimination diet and treatment with the and immunosuppressive drug and/or antibiotic 
trials are useful for IBD treatment and management5, 72. Dietary management includes the 
elimination diet, and novel protein source restriction is used to control the exposure of dietary 
antigens and may reduce intestinal inflammation101. Moreover, a specialized diet with high 
palatability, high digestibility, and easy absorption potentially treats some abnormal physiological 
conditions, such as lack of appetite, malnutrition, protein loss102. Drug treatment in dog IBD is 
determined by several factors, including severity and extent of disease, duration of illness, adverse 
effect of drug, clinician experience and treatment cost 100. Several immunosuppressive drugs have 
been reported to treat dogs with IBD effectively, including glucocorticoids 103 , and Cyclosporin104. 
Additionally, a combination of glucocorticoids and antibiotic regimens has been noted for their 
positive results in several studies5, 72. The suppression of gut microbes by antibiotics potentially 
reduce pathogenic bacterial colonization and attenuate the proinflammatory immune response 
occurring in the gut mucosa 105. Moreover, some antibiotics are reported to have an 
immunomodulatory effect, such as metronidazole106, 107, and may exert their effect synergistically 
with immunosuppressive drugs. 
In addition, the principal of reintroducing the healthy microbiome into the affected GI tract 
is considered a promising strategy for preventing, treating and maintaining the GI health 108-110. 
IBD treatment using probiotics and/or fecal transplant is currently in focus. Few studies have 
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confirmed the effect of lyophilized probiotic cocktail to suppress the inflammation in chronic 
enteropathy 5, 52, 109, 111-113. However, limited of the results regarding the efficacy of probiotic 
evaluation have been reported from a clinical trial study of canine idiopathic IBD 109, 114, 115. 
Additional prospective clinical study and trials are needed to determine the optimal treatment for 
dogs with IBD. 
The prognosis of IBD is evaluated by responses to treatment that can be observed 
subjectively and objectively 3, 25, 71, 90, 92, 97. Several clinicopathologic markers have been useful to 
assess treatment response and predict prognosis71, 91, 92, 98. IBD with complication from protein-
losing enteropathy and/or cobalamin deficiency is associated with adverse outcomes and poor 
prognosis. So, early awareness and sufficient treatment potential prevent those complications. IBD 
is mostly incurable with long-term complications despite receiving standard treatments that are 
typical combinations of food trial, antibiotics, anti-inflammatory and immunosuppressive drugs 
116. However, the therapeutic outcome of medical treatment appears to be multifactorial 117. 
Finally, the progressive-unresponsive IBD requires intestinal resection together with medication 
75 as most patients experience impaired quality of life due to complication and adverse effect from 
medical and surgical treatment. One of the alternative treatments that potentially accelerates 
therapeutic effects is the use of mesenchymal stem cell (MSC) administration 118-120 (described 
later). 
 
1.2 The Role of Gut Microbiota to Intestinal Immunity in Dog IBD 
 
1.2.1 Alteration of Gut Microbiome in IBD 
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Intestinal microbes substantially maintain host health by providing a defense barrier against 
pathogens, stimulating the immune system, and supporting the digestion and nutrition for 
enterocytes 121. Members of the intestinal microbiota produce various beneficial metabolites; for 
example, antimicrobial molecules, indole and butyrate affect immunomodulatory properties and 
protect against colitis 122-125. Additionally, the crucial contribution of the gut bacteria to the host 
homeostasis is the development of gut-associated lymphoid tissues (GALTs) generating 
gut‑specific immune responses and the prevention of colonization by pathogens. Studies in animal 
models demonstrated that intestinal bacteria are required for the progress of intestinal 
inflammation in IBD 124, 126-130, and the function of mucosal immune cells cannot be disconnected 
from the microbiota. Therefore, the alteration of bacterial balance secondary to disrupted mucosal 
homeostasis in the gut plays a pivotal role in IBD pathogenesis, including the loss of immune 
tolerance to endogenous flora 51, 131, 132 and greater sensitivity to active inflammation 48. The 
alteration of the gut environment, as well as dysbiosis during IBD, may allow the commensal 
bacteria to become opportunistic pathogenic bacteria, contributing to mucosal detriment, 
inflammation and invasive infection 24, 124. These alterations are well described in laboratory 
animal models, humans, and dogs with IBD 10. For example, adherent-invasive E. coli and 
Bifidobacteria adolescentis in humans induce both mucosal and systemic inflammatory Th17 cell 
133, 134. In addition, a study on the GSD breed has identified dysbiosis in association with 
differential high and low Tlr4 and Tlr5 expression compared to that observed in healthy 
Greyhounds 15, 26. Therefore, a dysregulated microbial community with genetic and environmental 
susceptibility affects the gut homeostasis contributing to IBD development. 
The interaction between bacteria and their host is crucial in IBD. Great variability exists in 
the gut microbiota in dogs, and the immunogenicity of the microbiota to the host also varies. The 
12 
 
results from recent studies indicate that the alteration of intestinal microbiota play a role in the 
pathogenesis of dog IBD 131, 135, 136 rather than particular agents causing IBD. Dogs with IBD have 
significantly altered microbiota composition either in the luminal or mucosal site compared to 
normal controls, and the common dysbiotic population corresponds to findings in humans. Most 
commonly, a decrease in the proportions of Bacteroidetes, especially the subsets considered to be 
a short-chain fatty acid producer 137, is observed to lead to impaired mucosal architecture and 
immune reactivity. Additionally, studies found an increase in Firmicutes (Clostridiaceae) 121, 131, 
135 and Proteobacteria (E. coli) 131, 135, 136, 138 and a high prevalence of invasive E. coli strain in the 
gut mucosa from IBD dogs 59, 131. However, these observed changes in the microbe community 
differed over time and stage of the disease, suggesting that a general dysbiosis, rather than infection 
with invasive pathogens, is associated with IBD. Therefore, a weakened mucosal defense, a 
reduction in beneficial microbes, and an aberrant immune response lead to perpetuation of 
intestinal inflammation131, 136. Notably, whether the dysbiosis causes disease or whether it is 
secondary to gut inflammation, is unknown. For these reasons, treatment using antibiotics, 
including Metronidazole and Tylosin, to attenuate the luminal dysbiosis is found to improve 
clinical signs in many cases 72, 105, 139. The dysbiotic population is plausibly controlled by 
antimicrobial activity per se or by the immunomodulatory effect of those antibiotics 106, 107. In 
addition, restoring the intestinal dysbiosis with beneficial bacterial subsets, such as with the 
introduction of probiotics, therefore may be a reasonable objective in the treatment of canine IBD 
121, 130. For example, treatment of mice with colitis with a probiotic cocktail VSL#3 increased the 
production of IL-10 and the percentage of TGF-b-expressing T cells 52. 
 
1.2.2 Intestinal Immune Responses in Animals with IBD and Dysbiosis 
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Mucosal immune response against gut bacteria plays an essential role in mucosal 
homeostasis. According to current knowledge, the resident microbiota regulates the development 
of specific immune cell subsets in the gut mucosa, including the Th17, innate lymphoid cells 
(ILCs), mucosal macrophage and regulatory T cells 124and the abnormal activation of these cells 
by dysbiosis potentially contributes to an uncontrolled inflammatory response in IBD cases. For 
example, a previous study reported that human intestinal mononuclear phagocytes show 
hyporesponsiveness to microbial stimulation under steady-state conditions, and this tolerance is 
disrupted in IBD 48. Additionally, dysbiosis propagates a pro-inflammatory immune response by 
increased TLRs activation and a reduction in mucosal IgA, leading to more pro-inflammatory 
cytokine production 26, 28, 48, 140 and immune cell activation, such as increased IgG+ plasma cells 
in lamina propria 27. In contrast, the anti-inflammatory cytokine is found to be decreased in 
dysbiotic condition 141, suggesting that it causes deregulation of regulatory T cell and activates the 
Th-17 cascade, thereby contributing to a disruption of gut homeostasis, as shown in other studies46, 
142. 
Additionally, local humoral immunity plays a crucial role through protective defense 
mechanisms by IgA binding against commensal bacteria. Previous studies showed that high IgA-
sorted bacteria were generally commensal and potentially caused the disease under specific 
predisposing genetic or environmental conditions 143, 144. Thus, possibly, some commensal 
microbial strains are far more effective in inducing mucosal immune response than others under 
IBD status. For example, phylum Proteobacteria is commonly increased in the CD patient 110, and 
human IBD study showed a higher level of IgG bound to the Proteobacteria subset, including E. 
coli 65, 67. However, in IBD, shifting a common IgA defense mechanism to an IgG-mediated 
response potential aggravates more inflammation in the gut mucosa in IBD. In comparison with 
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IgA, the IgG bacteria immune complex triggered more intensive immune response via immune 
cell activation, phagocytosis and antibody-dependent cell-mediated cytotoxicity 145, 146. Thus, the 
IgG is potentially responsible for ongoing proinflammatory milieu in dog IBD. 
Overall, the homeostasis of the gut microenvironment requires equity interaction between 
host immunity and gut flora. The alteration of the bacterial balance potentially causes disrupted 
mucosal homeostasis, including immune intolerance to endogenous gut flora and susceptibility to 
response to inflammation. Notably, the breakage of the microbiota balance either could be a cause 
or a consequence of impaired gut immunity, and future study regarding the interaction between 
host immunity and the gut microbiome is required. 
 
1.3 Overview of MSCs as a Novel Treatment for IBD 
 
1.3.1 Origins and Characteristics of MSC 
MSC is characterized by fibroblast-like-shaped, plastic-adherent, nonhematopoietic, 
multipotent progenitor cells isolated from an adult or from embryonic tissue 147. In general, adult 
tissue-derived MSC can be obtained from a variety of tissues, including bone marrow 148, muscle 
148, adipose tissue148, periosteum 148, umbilical cord 149, umbilical cord blood 150, Wharton Jelly 
151, and dermis 152, 153 and more. One of the most common sources of adult stem cell is adipose 
tissue due to the abundant cell yielded per weight of tissue derived from various anatomic regions 
154 and having practical accessibility in a clinic. 
Although, the MSC criteria are established, and some markers also have been identified, 
the actual nature, phenotype, and function are mostly unknown. At present, the MSC phenotype is 
determined based on the criteria of International Society for Cellular Therapy 155 and includes the 
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high expression of MSC markers—Sca-1, CD29, CD44, CD73 CD90 and CD105—and weakly or 
negative leukocyte markers and endothelial markers—CD11b, CD14, CD19, CD31, CD34, CD45 
and MHC II. In addition, MSC is considered an immune-privileged cell since the lack of 
costimulatory molecule CD80 CD86 and MHC II expression 156, 157 prevents them from immune 
recognition and supports the use of an allogenic MSC source 153. MSC migrates in response to the 
chemokines and are able to degrade the basement membrane for extravasation to the sites by 
activation of matrix metalloproteinases 157. This feature is useful for MSC to be delivered 
systemically in clinical application.  
MSC can be culture expanded ex vivo in up to 40 to 50 cell doublings without 
differentiation. Additionally, MSC has superior properties due to its capability to differentiate into 
various lineages originated from the mesoderm. This capability is controlled by stimulatory factors 
in the culture conditions, leading to differentiation in cell development, such as bone, cartilage, 
fat, and other connective tissues. Beyond the mesoderm lineages, previous studies have 
documented that MSC can differentiate to other lines including hepatocytes, neuron-like cells 158 
and pancreatic islet-like cells 159. 
One of the crucial features of MSC is their immunosuppressive properties identified in 
vitro and in vivo against inflammation in various kinds of disease, including SLE, graft-versus-
host-disease (GVHD), osteoarthritis and IBD 160-162. MSC behaves as the potent 
immunomodulators of the immune response (described later), although the exact mechanism 
responsible for MSC-mediated immunosuppression remains partly unknown. The suggested 




Overall, the MSC has superior properties, including multilineage potential; self-renewal; 
and being an easily accessible source of rich tissues that are isolatable and expandable in vitro, 
with exceptional genomic stability and few ethical issues 160. These support the MSC as a 
promising alternative cellular therapy in various immune disorders including SLE, graft-versus-
host-disease (GVHD), and osteoarthritis and IBD 160-162. 
 
1.3.2 Therapeutic Effects of MSC in IBD 
Cellular therapy with MSC has emerged as a promising new therapeutic strategy for 
managing inflammatory diseases, including IBD 160, 163, 164, because they have shown the 
remarkable immunoregulatory property in anti-inflammation and tissue regeneration with few 
side-effects and long duration of action in both in vivo 165, 166and clinical trials of IBD 167-169. 
In IBD, the number of animal studies have reported the effects of MSC administration by 
an i.v. or i.p route in ameliorating the inflammation, in both experimental IBD 166, 170-176 and 
clinical trials 168, 177-180. The positive responses of MSC therapy in IBD included improved clinical 
signs, reduced disease activity index and inflammatory score. Additionally, previous documents 
reported that MSC is the immune privilege cells with the ability to migrate toward the injury sites 
through chemoattractant gradients 153, 157 demonstrating by fluorescent trafficking study 163, 181, 182. 
These studies support that the systemic delivery of MSC could be a useful administration route in 
clinical application. 
Moreover, the recent human clinical trial showed the safety of allogeneic and autologous 
MSC treatment in chronic relapsing Crohn’s disease 179, 180, 183. Recent clinical studies on IBD 
using systemic delivery of allogenic MSC showed the safety outcomes in humans 179, 184-187, as 
well as in other species, including dog 168, 188 and cat 189. For example, a recent study documented 
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no detectable infection and adverse effect after MSC treatment in a moderate to severe UC patient 
in a clinical trial 187. Additionally, so far, no report has been issued regarding the potential of MSC 
to cause tumorigenesis after follow-up for approximately 137 months in 41 patients who received 
MSC treatment 190. Therefore, this evidence allows systemic delivery of allogenic MSC as 
practical, convenient and safe for clinical application. However, the risk that MSC will trigger or 
worsen malignancy from spontaneous malignant tumors and enhanced tumor development191, 192 
is still a concern due to immune suppressive activity and multiple chromosomal aberrations found 
in a mouse model 193, 194. Therefore, the need exists for further studies in this regard. 
In IBD treatment, MSC has been shown to modulate immune responses and reduce 
inflammation by suppressing the function of T, B cell, natural killer (NK), and macrophages 171, 
195-199; inhibiting maturation of monocyte to DC 160, 164, 200; and enhancing regulatory T cell 165, 201, 
M2 macrophage 164, 202, 203 and IL-10 production 165, 171, 175 at the mucosal sites. Although the actual 
mechanisms underlying immune modulatory activity of MSC are not fully understood, some of 
these mechanisms are assumed to require cell-cell contact dependent manners 171, 204 and/or 
paracrine effect 152 through secretory bioactive mediators including PGE2 205, 206, IL-10 165, 171, 175, 
207, TGF-β, insulin-like growth factor-1 (IGF-1) 201, indoleamine 2,3 dioxygenase (IDO) 206, 208, 
cyclooxygenase 2 (COX2) 201 and nitric oxide (NO) 201, 209. In addition, MSC inhibits the 
amplification of inflammatory signal by suppression of cytokine production, such as TNF-a, IFN-
g, IL-17 and IL-22, therefore leading to less immune cells recruitment to the sites and enhanced 
regulatory T cell 201, 210. 
Although no current evidence shows that MSC could differentiate to target cells, MSC is 
believed to exert a regenerative effect through secretory mediators, thereby contributing to tissue 
healing such as by cytokines and growth factors. Beyond the immune modulation, MSC also has 
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been shown to promote tissue regeneration and mucosal healing for IBD treatment by crypt 
proliferation as well as neovascularization 163, 203, 211. Although, the exact mechanism of the re-
epithelialization induced by the MSC remains unclear, MSC has been found to secrete significant 
levels of vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), basic 
fibroblast growth factor (bFGF), and CCL2 to enhance local neovascularization and healing 152, 
157, 203, 212, 213. Additionally, MSC is believed to have the ability to communicate with the resident 
tissue stem cells (e.g., intestinal stem cells) through Wingless and INT-1 (Wnt) signaling 214 and 
enhanced tolerance of mucosal cells against oxidative stress 172. Moreover, previous studies have 
shown the effect of MSC treatment to restore microorganism community profiles to resemble the 
normal healthy state 163. Therefore, the overall effect of MSC in treatment of IBD could be the 
summary effect of immunomodulation toward anti-inflammation, together with a regenerative 
effect to restore the homeostasis of the gut microenvironment, and these effects are essential 
especially in case of refractory and complicated IBD with fistula 215. 
 
1.3.3 Limitation of Conventional MSC  
MSC has advantageous properties that include multilineage potential, self-renewal, and an 
easily accessible source of rich tissue, that is isolatable and expandable in culture, with exceptional 
genomic stability and few ethical issues 160. A number of studies have demonstrated that 
conventional MSC can be used for multiple purposes including tissue repair, immunomodulation, 
and drug delivery 163, 164, 216-218. In IBD, the conventional MSC have been documented for their 
advantageous features and useful for treatment even in the complicated cases 179, 183-185, 215. 
However, some limitations are concerned for conventional MSC transplantation in clinical 
treatment for IBD including safety, adverse side effects, and consistent efficacy.    
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The awareness of potential tumorigenicity of transplanted MSC and potential adverse 
effects have been a drawback for clinical application 157. Although MSCs are believed to have 
differential ability, they are restricted to the mesoderm lineage with low risk of tumor formation 
157. The safety of stem cells to treat the patient is based on prioritization of concerns. So far, no 
evidence regarding tumorigenesis by MSC treatment has been shown 219. However, the risk that 
MSC stimulates worsened malignancy by supporting tumor development 191, 192 is still a concern 
due to their immunosuppressive activity 193, 194. Additionally, few adverse effects have been 
documented after MSC administration; however, a limited number of the patients have been 
approached, and more evidence is needed to confirm this conclusion. Therefore, a continued need 
exists for further studies in this regard.  
A significant limitation of autologous MSC treatment is that it requires a period for cell 
expansion in the culture that is not convenient and practical for acute injury application. 
Additionally, some patients might have limited access to their cells, as some diseases 220, 221 and 
aging potential reduce their stem cell capacity 222, and the MSC derived from younger donors are 
found to be more active immunologically 223. Thus, the potential solution would be a source of 
allogenic MSC, which may be prepared and ready to use. However, the use of conventional 
allogeneic MSC for larger scale in clinical cellular therapy is also subject to several significant 
drawbacks, including donor-to-donor MSC variability, the limited proliferative capacity of older 
MSC 171, 224, the costs for donor screening, and the time and expense associated with expanding 
MSC in primary culture 225-227. Therefore, inexhaustible cell sources of MSC with uniform 
phenotype and standardized function are desirable for the consistent therapeutic outcome. 
Another concern is the varying efficacy of treatment by conventional MSC, which ranges 
from adequate to ineffective outcomes 190, and this is one of major concerns for MSC 
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transplantation. For example, some of GVHD studies have shown the failure of MSC treatment to 
protect graft rejection in an in vivo animal model 217, 228. Moreover, studies in human MSC 
treatment found no effect of conventional MSC unless those MSC had been preactivated by 
inflammatory stimuli 229, 230. Although, the treatment effect probably depends on the experimental 
designs, including the MSC dosage and administration route 207. The ineffective result from 
conventional MSC treatment is probably associated with the acquisition of cytogenetic 
abnormalities 157, altered phenotype 190 and hypofunction 207, which occur after long-term culture. 
Thus, modification of MSC that promotes a high quality of MSC with consistent functional activity 
and stable phenotype is still the ideal for MSC therapy. 
Overall, the limitation of using conventionally unstimulated MSC; including safety, quality 
of cell, genotypic and phenotypic stability, and functional activity for consistency outcome, is a 
concern when using cellular therapy. Specifically, some limitations (i.e., cell quality, renewal 
capacity, and functional activity) are probably solved by using modified MSC, such as activated 
MSC or iPSC-derived MSC (all described later in section 1.4). 
    
1.4 Ex-vivo Activation of MSC to Improve Therapeutic Activity in Inflammatory Diseases 
 
1.4.1 Preactivated MSC by Toll-Like Receptor Agonists and Cytokines  
Despite the promising outcome using conventional MSC therapy, challenges remain in the 
MSC application. One of the issues addressed is the variable or ineffective outcome after MSC 
administration described previously 217, 228. For example, studies in human MSC found no effect 
of conventional MSC in experimental assays, and the immune suppressive effect was retrieved 
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only in the preactivated MSC by inflammatory stimuli 153, 190, 229, 230. Therefore, enhancing the 
capability of MSC by inflammatory mediator activation improves the treatment efficacy. 
Previous studies have found an increasing therapeutic effect of MSC by incubating with 
inflammatory stimuli and/or cross-talking with damaged cells, whereas the nonactivated cells may 
be incapable 152, 207, 231-233. The reason is that the final immunomodulatory outcome of MSC is 
likely influenced by the microenvironment cues at the site of inflammation 234. Thus, they migrate 
and get activation by the proinflammatory stimuli including IFN-g 231, 232, 235, 236, TNF-a 236, and 
LPS (TLR4 agonist) 235, 237, as well as Poly(I:C) (TLR3 agonist) 237. Previous studies on mouse 
and human MSC found that the resting MSC did not have significant immunosuppressive activity 
in the treatment of IBD. Although stimulatory molecules, i.e., LPS, IFN-g, and TNF-a, could 
activate the NF-kB pathway in MSC within 1 hour 234, 238, 239, their immunomodulatory functions 
had to be elicited by an incubation time of at least 24 hours to several days 203, 232. IFN-g- and 
Poly(I:C)-preactivated MSC showed significant therapeutic effect in the mouse model of colitis 
232, 240 in contrast to LPS-treated MSC 147, 240. Additionally, one study of canine MSC (cMSC) 
reported that MSC did not affect the unstimulated PBMC because an absence of inflammatory 
stimuli was present in the culture environment, and cMSC was able to inhibit proliferation in the 
stimulated PBMC, which was demonstrated by the mixed lymphocyte reaction (MLR) 231. In 
addition, preactivated MSC could be induced by a very low concentration of inflammatory 
cytokines (i.e., 0.4 ng/ml of cytokine), and a high effect was also observed 233. Thus, the 
inflammatory milieu even in a low amount of cytokine, plays an important role to determine the 
final effect of MSC on target cells.  
Evidence has been reported that MSC secretes more growth factors after an experience 
with cytokine milieu, hypoxia and TLRs agonist 207, 241, 242. IFN-g, LPS, and Poly(I:C) rapidly 
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induced and activated the NF-kB pathway in human and mouse MSC 237, 239, although resting MSC 
within the noninflammatory environment could constitutively produce some mediators, as 
described previously. Preactivated MSC with TNF-a, IFN-g, LPS, Poly(I:C) or IL-1B have been 
found to produce significant amount of cytokines, growth factors, chemokines and adhesion 
molecules including IL-6 208, 231, 242, 243, IL-8 231, 237, 242, 243, IL-10 207, HGF 231, TGF-B 242, PGE-
2236, IDO 242, 243, VEGF 231, 244, CXCL2 245, CCL2245, CXCR3207, CCL5243, 245, CCR10235, 
CXCL10235, 237, ICAM-1207, and VCAM-1207. In addition, upregulated chemotactic ligand induced 
by IFN-g, TNF-a and IL-1B preactivation enhanced the migratory ability to the affected area, as 
shown in a tracking study 201, 207 and migratory assay 203, 245. Importantly, some mediators derived 
from preactivated MSC likely induce a pro-inflammatory milieu such as IL-6 (neutrophil 
chemotaxis) and IL-8 rather than anticipated immunosuppressive activity. These effects suggest 
that the net outcome from preactivated MSC occurring at the inflammatory sites is probably 
bidirectional activity, representing either inflammation or anti-inflammation, as suggested in 
several studies 207, 234, 243, 245. However, no concordance exists in the literature regarding the range 
of concentration in each stimulus for driving the MSC to immune system inhibitory properties. 
Therefore, further study to obtain suitable phenotypes and functions for optimal activation when 
treating diseases remains a challenge and is still a need. 
Preactivated MSC with a variety of inflammatory cytokines and TLRs potentially change 
their phenotype, thereby contributing to an altered function of cells. IFN-g stimulation induces 
MSC to express PD-L1 236, 246, 247, and it is thought to be an important surface marker for MSC to 
suppress T cell proliferation. Moreover, MHC II is upregulated by IFN-g stimulation, suggesting 
the additional roles of MSC as an antigen-presenting cells 152, 207, 234, 248. However, the remaining 
surface markers, including CD34, CD80, CD86, CD105, and CD 106, are not changed by the IFN-
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g, LPS, and Poly(I:C) treatments 234, 237. Additionally, no evidence exists to show that this 
preactivation alters the MSC Tri-lineage differentiating ability 237. 
Most of data regarding the preactivated MSC have been obtained mainly from human and 
mouse studies. Some significant differences exist between mouse and human MSC in terms of the 
mediators driving the inflammatory suppression 234. For example, in human MSC and primate 
MSC 230, 235, 249, IDO is involved in the suppression of T cell proliferation, and the activated hMSC 
with IFN-g and TNF-a enhances the degree of suppressing activity 232, 242. However, mouse MSC 
have no IDO production, and their immune suppressive activity is mediated by Nitric Oxides (NO) 
190, 209, 233, 243. These data suggest that species variation in the immunosuppression mechanism may 
be a concern, although majority of MSC action in response to those stimuli is roughly in 
concordance between interspecies. Moreover, in other species, including dogs, knowledge of the 
overall alteration of features and function of MSC by preconditioning with those stimuli is still 
mostly unknown. Therefore, the extensive studies regarding primed MSC and their action to 
immune system are required for understanding the nature of dog MSC. 
Overall, although the immunomodulatory pathway induced by TLR-activated MSC 
remains controversial, these MSCs potentially enhance the immunomodulatory mediator 
production and increase the therapeutic effects. Several studies show the increase of anti-
inflammation and augmentation of tissue regeneration through the secretory factors, as well as 
cell-cell contact activity. These approaches would be the way to improve MSC efficacy to obtain 
a significant effect and consistency result with IBD cellular therapy. However, more studies are 
required to determine the appropriate way to activation to ensure the beneficial outcome for IBD 




1.4.2 Induced Pluripotent Stem Cell-Derived MSCs (iPSC) 
MSC exerts beneficial effects that are immunomodulatory and regenerative to treat a 
variety of injury and inflammatory diseases including IBD. According to their immune privilege 
and ability to migrate to the inflammatory sites after intravenous administration, the allogeneic 
transplant of MSC is believed to be useful, convenient and safe for clinical application. However, 
several essential drawbacks interfere with the practical application of this application at a larger 
scale, including the limited proliferative capacity of senescence MSC 224, donor variability, donor 
screening expense, and the time and cost associated with expanding MSC in primary culture 225-
227. Additionally, previous studies have reported inconsistent outcomes of allogenic MSC 
treatment 190, 217, 228, suggesting from the different phenotype, function, uniformity and cell quality 
that MSC may be altered in long-term cell culture 157, 190, 207, thereby leading to a reduced 
therapeutic outcome 250, 251. Therefore, inexhaustible alternative sources of MSC that are uniform, 
standardized and renewable, with consistent therapeutic outcomes, are desirable. 
Stem cell-based therapy using iPSC-derived MSC (iMSC) is considered a promising 
therapy. Regarding the limitation of conventional adult stem cells, the iMSC is considered an 
alternative source that accelerates large-quantity production, with the superior benefit of quality 
control, greater expandability of homogenous cell population, and less pro-tumor potential 160, 252-
254. iPSC can be generated from an adult somatic cell (i.e., a fibroblast) by reprogramming those 
cells to a pluripotent state. Thus, iPSCs are similar to embryonic stem cells in term of morphology, 
gene expression, teratoma formation and in vitro differentiation 153, 255. After being differentiating 
to the MSC lineage, iMSC has features that are similar or superior to conventional MSC 253. For 
example, iMSC showed an increased proliferation capacity; they achieve their renewal capacity 
for 40 passages without losing of plasticity or showing senescence 253. Several studies have 
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determined that iPSC-derived MSCs are likely similar to conventional MSC regarding phenotype 
and function 163. Additionally, iMSC is free of ethical concern and has the potential to be modified 
for personalized medicine (i.e., drug delivery or anti-inflammatory purposes), as well as being 
genetically engineered to achieve a safe profile 255. 
The ability of iPSC-derived MSC to suppress inflammation in vivo has also been 
demonstrated in mouse models, including colitis 163, allergic airway disease 256, limb ischemia 253, 
and myocardium infarction 257. These studies show that iMSC has equivalent 256, 258 or superior 
efficacy 253 compared to conventional MSC in the context of features, anti-inflammation and tissue 
regeneration. Overall, iMSC is a new alternative MSC source that facilitates excellent benefits of 
more exceptional expandability and easy quality control, which result in consistent therapeutic 
outcomes in line with the conventional outcome. However, future studies regarding the long-term 
follow-up of safety and efficacy of iMSC treatment need to be evaluated carefully before clinical 
translation 153.   
 
1.4.3 Treatment with MSC Secreted Factors 
 MSCs are multipotent stem cells that have advantages for multipurpose therapies, 
including tissue repair, immunomodulation and drug delivery 163, 164, 216-218. These cells are 
conveniently accessible sources; isolatable; in vitro expandable, with genetic stability; and are free 
of the ethical issue 160. In many diseases, including IBD, conventional MSCs have shown their 
efficacy in treatment even in the complicated cases179, 183-185, 215. MSCs have been shown to 
modulate immune responses and reduce inflammation by suppressing immune cells, and enhanced 
anti-inflammatory cytokine production. They also support tissue regeneration and 
neovascularization through secretory mediators, cytokines, chemokines and growth factors. 
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Although the exact mechanisms underlying MSC function remain to be explored, part of the 
mechanism is assumed to be operated by secretory mediators and paracrine effect 152.  
Some limitations have been noted regarding the use of MSC cellular therapy in IBD. 
Several studies found inconsistent therapeutic outcome after MSC injection 217, 228, and one 
possible reason for low efficacy was due to a low number of cells distributed to target tissue 163. 
This inefficacy may be caused by an unequal distribution of MSC in some organs and/or 
inadequate inflammatory signals to attract MSC to sites. Additionally, donor variation and cell 
damage or senescence before administration are considered the factors of a reduced number of 
cells at the affected tissue. In addition, the MSC therapeutic effect in IBD does not depend on their 
full engraftment but mainly on the secretory mediators that contributed to tissue repair 152, 203. 
Although, it is suggested that the MSC mechanism requires cell-cell contact interaction, a number 
of Transwell co-culture systems have demonstrated that the paracrine/endocrine effect provides 
preferential action and yields a comparable result in the cell-cell contact coculture 209, 235. 
Therefore, when therapeutic efficacy in IBD is being augmented, the MSC secretome provide an 
alternative way for the thorough systemic delivery of active mediators from MSC to the overall 
body including GI mucosa. 
   As described previously, MSC secrets secretory bioactive mediators including PGE2 205, 
206, IL-10 165, 171, 175, 207, TGF-β 152, IGF-1152, 201, IDO206, 208, COX2201, VEGF231, 244, 259, CXCL2245, 
CCL2152, 245, and NO201, 209. These mediators play a role in immune modulation and intestinal 
healing in IBD. IGF-1 was reported to increase intestinal regulatory T cells, improve intestinal 
function and promote enterocyte proliferation 201. The secretome includes the extracellular vesicles 
and soluble mediators that are constitutively produced by most cell types. The vesicles may contain 
a variety of bioactive molecules, which include mRNAs, microRNAs, and proteins. Previous 
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studies have reported the use of secretomes either prepared by MSC condition media or extracted 
from microvesicles/exosomes in the treatment of colitis. In these studies, the concentrated 
condition media derived from the MSC culture was administered, and the treatment with secretome 
ameliorated the colitis, which improved the clinical scores, reduced inflammation, and produced 
less pro-inflammatory cytokines 203, 260. One study documented the degree of improvement that 
was correlated with increased secretome dosage and frequency of injection 203. 
The treatment of IBD using the cell-free-based technique is compelling according to in 
vitro and in vivo models. The MSC-derived secretome overcame some limitations of cellular 
therapy, including allogenic DNA contamination in the recipient, risk of tumors originating from 
the transplanted cells, and cell density at the site of action, which resulted in a consistent 
therapeutic effect. Additionally, the method used to generate the secretome for larger scale usage 
or clinical applications with high-quality control would be practical. However, some pitfalls must 
be noted, including the cost of production, frequent administration and stability of mediators. The 
results of a mouse study showed that nine times more MSC was required for making secretomes 
compared to the number needed for cell therapy, and multiple doses were needed, which required 
concentrated filtration to the final optimal concentration 203. Therefore, the cost of secretome 
production increased more than the cost of MSC cellular therapy. Additionally, some secretory 
mediators occurred in low amounts and were unstable or exhibited short-lived action, such as NO 
201, so further processing may be required to preserve and maintain the quality. Due to limited 
knowledge about which secretory molecules are produced by MSC, the secretome composition 
should be carefully evaluated to ensure a positive result and to prevent the presence of harmful 
components 201. Overall, the use of the MSC-derived secretome is a promising treatment option 
for many diseases, including IBD. The positive therapeutic effects have been demonstrated by 
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several studies, for example, promoting intestinal re-epithelization and inflammation control. 
Future studies are needed to identify the secretome composition and assess the safety and side 
effects of the secretome in the long run. 
 
1.5 Effect of MSC Treatment on Osteoarthritis 
 
1.5.1 Altered Joint Environment in Osteoarthritis  
 Osteoarthritis (OA) is considered the most common joint disease diagnosed in both humans 
and animals261, 262. OA affects approximately 20% of the dog population 263, 264, and once it is 
established, life-long management is required. OA in dogs is usually described as a multifactorial 
disease and considered to largely resemble human OA 265. Genetics and environmental risk factors 
including being overweight, pure large breed background, and lifestyle 266-268 considerably affect 
the development and disease progression of OA 269. Male 267 and neutered dogs 270 have an 
observed higher prevalence than females since sex hormones and activity levels are also thought 
to exacerbate the disease condition. These predisposing factors interact to result in the 
development of an immune response that destroys the joint microenvironment, including the 
cartilage, synovium, and subchondral bone 271. In addition, canine OA is thought to be a 
degenerative disease that is typically found in middle to senior age dogs 262, 272. The abnormal signs 
develop after long-term destruction of the joint, and diagnosis occurs later after deterioration of 
the affected structure and impaired mobility 273. Thus, half of diagnosed cases are found within the 
age range from 8-13 years 263.  
 Clinical signs are commonly described as lameness, stiffness, painful joint(s) with chronic 
progressive joint degeneration and an abnormal limb appearance, including cracking joints, 
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swelling, and muscle wasting 261, 262, contributing to structural and biomechanical joint 
abnormalities with noticeable gait disturbances. The stifles, hip, and elbow are commonly affected 
joints based on several studies 261, 262. OA pathology is characterized by chronic active 
inflammation with possible findings of cartilage degeneration, an abnormal synovial membrane 
with inflammatory cell infiltration, subchondral bone thickening, and osteophyte formation 262, 272, 
274.   
The joint damage is probably triggered by single or chronic physical injury induced by 
mechanical force to the joint. Affected chondrocytes react to the injury by secreting catabolic 
enzymes such as matrix metalloproteinase (MMPs) 275-277 and triggering inflammatory cues 
including TNF-a, IL-1B, and IL-6 with subsequent innate and adaptive immune activation 275-277. 
Additionally, IL-1B has been reported to induce apoptosis of chondrocytes and synoviocytes 278, 
enhancing levels of MMPs including MMP1 and MMP13 and resulting in the proteolysis of 
collagen type II and proteoglycans, which are significant components of the extracellular matrix 
in cartilage (ECM) 272, 279 and are replaced by fibrosis via deposition of collagen type I and 
fibronectin. In contrast, IL-10, IL-13, and TGF-b from regulatory T cells have been shown to have 
a counterbalancing effect in terms of anti-inflammation, suppression of MMP production and 
support of collagen type II and aggrecan synthesis 279. Thus, the inflammatory milieu affects not 
only reduced synthesis but also accelerated destruction of critical components of the ECM 271. 
Adaptive immune cells are activated by pro-inflammatory mediators and migrate to the 
joint in response to chemokines. A greater number of inflammatory cells, including DCs, NK cells, 
B cells, Th1 subset cells, CD8+ T cells, and macrophages, are found in synovial fluid and 
synovium derived from OA tissue 271, 274, 276, 277. Previous studies have shown that activated 
immune cells infiltrate sites and release additional IL-1B, IL-2, IL-6, IL8, IFN-g and TNF-a 271, 
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274. These cytokines potentially affect downstream activation of the STAT1/STAT3 and NF-kB 
pathways 271, 274, leading to the upregulation of proinflammatory genes 279. In addition, the release 
of VEGF increases vascular permeability and neovascularization in synovial tissue, resulting in 
increases in fluid, cell infiltration and pain in the joint. Interestingly, an increase in regulatory T 
cells was observed in tissue derived from an OA patient. However, low levels of IL-10 were 
produced by those cells, indicating a regulatory T cell dysfunction 280 and insufficient levels of 
anti-inflammatory cytokines in the micromilieu. Therefore, disruption of homeostasis toward a 
catabolic state activates a repetitive cascade of proinflammatory events, resulting in a chronic 
relapsing course of joint inflammation and destruction 271.  
 
1.5.2 MSC Effects on Cellular Responses in the Joint Microenvironment 
 OA, also referred as degenerative joint disease (DJD) or osteoarthrosis, is considered one 
of the most common degenerative diseases caused by multiple risk factors that potentially 
contribute to the development of chronic inflammation of the joint to culminate in structural 
damage and painful, impaired limb function (as described previously). Previous studies have 
reported that the available medications for OA treatment, including nonsteroidal anti-
inflammatory drugs (NSAIDs) and analgesics, significantly alleviate the pain and control the 
inflammation in the joint 281. However, they are not capable of completely eliminating the 
inflammation and halting disease progression 264. A combination of treatment with drugs, food, 
and physiotherapy is commonly used for OA management in the clinic 282. To date, no effective 
therapy has been found to completely treat and restore joint health in OA 283. Thus, an alternative 
treatment that is able to modulate immune suppression with potential regenerative effects on joint 
tissue would be a promising treatment for OA. 
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A number of MSC studies have shown promising results in the treatment of OA both in 
animals and humans 284-288. MSCs exert remarkable immunomodulatory properties in term of anti-
inflammation as well as tissue regeneration, as shown by local 285-287 or systemic treatment 287-289. 
The beneficial outcomes of MSC treatment include reduced inflammation in the synovial tissue 
and chondrocytes, increased chondrogenesis 285, 288, and improvements of range of motion 286 and 
lameness 285, 286. Regardless of immunomodulation, previous studies have shown other remarkable 
properties of MSCs, including anti-fibrotic and anti-apoptotic effects and oxidative stress 
prevention, which affect all cell types in the joint including immune cells, chondrocytes, 
synoviocytes and fibroblasts 265. MSCs potentially suppress inflammation by inhibiting the activity 
of immune cells, including T cells, B cells, and macrophages, and stimulate regulatory T cells to 
secrete more IL-10 231, 280. A reduction of proinflammatory mediators (i.e., IL-1B, IL-6, IL-8, TNF-
a and MMPs) with a subsequent increase in chondrogenesis has been reported in OA joints 
receiving MSC treatment 278.  
Previous clinical trials using MSC therapy have demonstrated its safety with rare 
occurrences of adverse effects and long-lasting treatment effects after MSC transplant 285, 286. For 
example, previous studies have reported no severe adverse effects or complications after systemic 
delivery of MSCs in a clinical trial of spontaneous OA 287. Additionally, a safety study of intra-
articular MSC transplants in dogs and humans reported rare occurrences of side effects (i.e., joint 
swelling in 5% of cases) 285 as well as no tumorigenicity in long-term follow-up analyses (i.e., 6 
months-1 year) 286, 287. One clinical trial in dogs showed an 80% response rate and the ability to 
discontinue other medications for one year after intra-articular MSC injection 285. This evidence 
supports MSC treatment as practical, effective and safe for OA treatment in the clinic. 
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Overall, an imbalance toward a pro-inflammatory milieu activates recurring joint 
destruction with fibrosis, which causes chronic pain, structural deformity, gait disturbance and a 
reduced quality of life. A comprehensive treatment of OA would function to suppress the 
inflammation together with regeneration of the vital health of the joint. Of critical importance, 
MSCs effectively manage the joint microenvironment to achieve a less catabolic state and support 
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CHAPTER 2: HUMORAL IMMUNE RESPONSES DIRECTED AGAINST GUT BACTERIA 





Background: Inflammatory bowel disease (IBD) in dogs is a clinical disease associated with signs 
of intestinal inflammation involving the large and small intestines, as well as intestinal 
dysfunction. Although it is not clear what triggers the intestinal inflammations in IBD affected 
dogs, we hypothesized that the disease may be mediated, in part, by an abnormal immune response 
directed against intestinal bacteria. 
Objective: To comprehensively investigate the humoral immune response against gut bacteria in 
dogs with IBD, we conducted studies to determine whether dogs with IBD have more IgG-binding 
bacteria, and we hypothesized that dogs with IBD have a greater amount of immunoglobulin (Ig) 
produced against their gut microbiota. The studies also aimed to identify the source of Ig 
production and investigate the potential consequence of having Ig-binding bacteria to trigger an 
inflammatory response. We hypothesized that Ig is locally produced and has potential to induce a 
greater inflammatory reaction by IgG-coated bacteria than bacteria from the healthy gut. 
Methods: Stool and serum were collected and processed for flow cytometry to total the binding 
of IgA and IgG in the evaluation of the humoral immune response to gut bacteria in dogs with 
IBD. Further investigations of the source of antibody production and potential consequences 
caused by immune responses were performed via bacterial flow cytometry analysis, macrophage 
activation and cytokine production. Moreover, the immune targets to specific bacterial subsets 
were analyzed via sequencing and microbiome analysis. 
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Results: Dogs with IBD have substantially greater percentages and overall binding of IgG and 
IgA in their intestinal bacteria than healthy dogs, and the primary production of anti-bacterial 
antibodies occurs locally in the gut rather than systemically. The IgG-binding bacteria triggered 
an increase of phagocytosis and pro-inflammatory cytokine production by macrophages. 
Moreover, Actinobacteria (Collinsella genus) was the preferential target for the mucosal IgG 
immune response to dysbiotic bacteria.  
Conclusion: In dogs with IBD, the mucosal antibody binding to commensal gut bacteria was 
substantially greater than it was in healthy dogs, and these Ig-binding bacteria trigger the pro-
inflammatory response. Furthermore, anti-bacterial antibody targets a specific phylum, which may 




In dogs, inflammatory bowel disease is characterized by clinical symptoms of GI 
dysfunction (diarrhea, malabsorption, and weight loss) 1, 2 and macrophage and lymphocyte 
infiltration into the submucosa and mucosa. Studies have demonstrated that the dysbiosis 
development and changes in the gut environment favor the increased growth of pathogenic bacteria 
and inflammation, leading to intestinal injury in IBD3. Other factors associated with IBD in both 
humans and dogs include environmental and genetic factors4, 5. In humans, inflammation in IBD 
is considered mediated by both humoral and cellular immune mechanisms6-8. Furthermore, the 
investigations on human IBD (e.g., Crohn’s disease and ulcerative colitis) have focused on the 
functions of immune responses related to commensal gut bacteria rather than the immune 
responses related to dietary antigens or anti-mucosal antibody9-12.  
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Previous studies on dogs with IBD have reported humoral immunity dysregulation 
specifically with the decreased production of the overall amount of gut IgA13. For example, both 
lowered mucosal IgA production and high pro-inflammatory cytokine productions by mucosal 
immune cells (T cells and macrophages) have been documented in dogs with IBD13-15. However, 
previous studies have not investigated the specificity of gut Ig in dogs. One study in dog IBD 
identified a high level of plasma cells, which is in line with the production of local IgG in the 
lamina propria16, 17. 
Studies in humans showed that there was a substantially high level of fecal bacteria bound 
to IgG, specifically for patients with ulcerative colitis (UC) and Crohn’s disease (CD) 12, 18, 19. 
Moreover, studies indicated that some IBD patients have a high level of IgA+ bacteria12, 20. 
Importantly, in CD patients, IgA and IgG antibodies were identified to preferentially bind with 
specific pathogenic bacteria, such as Pseudomonas fluorescens, E. coli, and Clostridium 
coccoides21-23. 
In dogs with IBD, there is a limited understanding of the recognition of antibody in gut 
bacteria. A previous report found that the microbiome in healthy dogs is very different from that 
of dogs with IBD and specific phyla are predominant, causing a dysbiosis state24, 25. For example, 
AlShawaqfeh et al. established a dysbiosis index for determining the level of disruption of normal 
flora by bacterial overgrowth associated with the clinical symptoms of dogs with IBD26. Thus, in 
the current research, the humoral immune responses to gut bacteria in dogs with IBD were 
investigated compared to those of healthy dogs. To address the evaluation of the quantity of IgA 
and IgG antibodies bound to the surface of fecal bacteria, flow cytometry was performed. We also 
examined the existence of circulating anti-bacterial antibodies found in blood using serum 
incubated with an isolated bacterial strain and quantitate using flow cytometry analysis. To identify 
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whether the bacterial antibodies presented in dogs with IBD target a particular bacteria, fecal 
bacteria with high levels of surface IgG were flow cytometry sorted and subjected to 16S rRNA 
sequencing with subsequent microbiome analysis. Finally, through in vitro assays, we examined 
the IgG-bound bacteria impact on gut health by affecting the host macrophage activation and innate 
immune response. This study provides new insights on the pathogenesis of IBD in dogs and 
proposes that the local humoral immune response against gut bacteria has a significant role in the 
disease etiology and progression. In addition, this research extends further to expound on the 
potential value of a spontaneous IBD model in dogs to investigate the microbiome modulation and 
novel immunotherapies. 
 
2.3 Materials and Methods 
 
2.3.1 Study population 
A prospective observational study was conducted at the Colorado State University 
Veterinary Teaching Hospital (CSU-VTH). All animal studies were approved by the Clinical 
Review Board (CRB) (#VCS 2016-084), and the Institutional Animal Care and Use Committee 
(IACUC) at CSU. Dog owners were informed regarding the study protocol, and consent forms 
were obtained. Twenty-nine dogs, including 20 dogs diagnosed with IBD and 9 healthy control 
dogs, were evaluated in the study. 
 
2.3.1.1 Dogs 
This study recruited twenty dogs (14 males and 6 females) that had IBD with persistent 
symptoms of gastroenteritis, such as diarrhea, vomiting, and weight loss, for at least 3 weeks. To 
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confirm the IBD diagnosis and rule out the possibility of intestinal lymphoma, all dogs with IBD 
underwent an endoscopic examination and biopsy. The majority of the animals had a prior food 
trial, which was inclusive of a novel protein, hydrolyzed protein, and elimination diet for more 
than 3 weeks, and no obvious responsive result was found. The dogs did not have a recent history 
of receiving immunosuppressive medications and were free from other diseases causing chronic 
GI disease symptoms, including renal disease, metabolic disease, parasitic disease, pancreatic 
insufficiency, and hepatic disease. The research intentionally omitted German Shepherd dogs 
because the breed is recognized for being susceptible and prone to defective intestinal IgA and 
IgG27, 28. 
All IBD dogs received a clinical assessment, including a disease activity index evaluation 
(Canine Inflammatory Bowel Disease Activity Index; CIBDAI29 and Canine Chronic Enteropathy 
Clinical Activity Index; CCECAI30), a fecal examination for parasites, a complete blood count 
(CBC), and a serum chemistry profile. The H&E stained intestinal biopsy specimens from the dogs 
with IBD underwent a WSAVA histopathologic score evaluation1, 31 by a board-certified 
veterinary pathologist. Additional tests performed in IBD dogs included the serum folate 
concentration and serum cobalamin concentration profile (Gastrointestinal Laboratory, Texas 
A&M University, TX). 
 
2.3.1.2 Clinical healthy control animals 
Nine clinically healthy dogs (4 males and 5 females) age-matched to the IBD dogs were 
recruited in the study. These dogs were client owned and were assessed for a health checkup at the 
CSU-VTH. Based on the history and normal physical examination, these animals were considered 
free from any clinical sign indicating gastrointestinal disease, and the animals had no recent history 
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of immune-mediated disease or immune suppressive medication usage. All dogs also had a CBC 
and serum chemistry profile performed, and all evaluations were within the normal limits. 
 
2.3.2 Sample collection 
Feces and blood samples from all study dogs were collected and immediately stored at 4°C 
before sample preparation, which occurred within 4 hours after obtaining the samples. Blood was 
spun for serum separation, and serum samples were stored at -80°C. Stool samples were obtained 
by spontaneous defecation and/or rectal palpation. Fresh stool samples were processed to generate 
a fecal bacteria suspension as previously described18. Briefly, 0.5 g of stool was homogenized in 
24.5 ml of sterile-filtered phosphate buffered saline (PBS; 0.2 µm-filtered) using vortexing, 
followed by centrifugation at 700 x G for 5 minutes to separate the large particles from supernatant 
containing rich bacteria. The fecal bacteria suspension (supernatant with floating bacteria) was 
collected and stored in 1 ml aliquots at -80°C until use.  
 
2.3.3 Flow cytometry 
The fecal bacteria suspension from the freezer was thawed and centrifuged at 10,000 x G 
for 5 minutes to obtain a bacterial pellet, which was washed with 1 ml of PBS one time. To measure 
the Ig-binding fecal bacteria, the bacterial pellet was resuspended in 100 µl of rabbit anti-dog IgG-
Alexa Fluor 647® conjugate (Jackson ImmunoResearch Laboratories, PA, USA; diluted 1:200 in 
PBS plus 1% BSA) or with a solution of goat anti-dog IgA-FITC conjugate (Lifespan Biosciences, 
MA, USA, also diluted 1:200 in PBS plus 1% BSA) and incubated for 30 minutes on ice. The 
suspensions were pelleted, washed twice, and then fixed for 10 minutes in a solution of 4% 
paraformaldehyde (PFA). After washing, the bacteria pellets were resuspended in 380 µl of PBS, 
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plus 20 µl propidium iodine solution (PI; 1 g/ml; Sigma-Aldrich, St. Louis, MO, USA), which was 
added to each sample immediately prior to flow cytometry analysis. Note that the optimal 
concentrations of antibodies and PI used in this study were obtained after passing the processes of 
antibody titration and optimization for the staining condition. 
For the detection of serum IgG antibody that is specific to intestinal bacteria, 6 stock 
bacterial isolates of Escherichia coli (E. coli) from the stool of healthy dogs (n= 3) and IBD dogs 
(n= 3) were generated as subsequently described. The bacteria in overnight cultures were collected 
and incubated with serum from healthy dogs and dogs with IBD for the detection of IgG binding 
following a previous study method32. Briefly, each test serum sample was diluted 1:200 in PBS 
plus 1% BSA, added to E. coli in suspension and incubated for 30 minutes on ice. The samples 
were subsequently washed twice, incubated with the rabbit anti-dog IgG-Alexa Fluor 647® 
conjugate, and analyzed by flow cytometry as previously described. 
Flow cytometric analysis in this study for IgG and IgA binding bacteria was performed 
using a Beckman Coulter Gallios flow cytometer (Brea, CA, USA). The analysis was examined 
on 100,000 PI-positive events gating based on bacterial size and complexity. The purpose of the 
PI staining was to include bacteria (DNA+) for analysis and exclude debris without nuclear material 
(DNA-). Flow cytometry data were further analyzed using FlowJo Software (Ashland, OR, USA). 
The analysis included the percentage of positive fluorescent cells and the fluorescence intensity of 
IgG+ or IgA+ cells. The background fluorescence levels were determined using bacteria without 





2.3.4 Isolation of E. coli intestinal strains and evaluation of anti-bacterial antibodies present in 
serum 
To evaluate the presence of anti-bacterial antibodies in the serum of dogs with IBD and 
healthy dogs, six varying isolates of E. coli were analyzed, three of which were obtained from the 
feces of dogs with IBD and the other three from healthy dog feces. Although the study 
acknowledges that various bacteria species were identified by antibodies through the fecal flow 
cytometry (see below), we argued that E. coli found in the gut might propagate readily in pure 
culture and overall it could be a great substitution for enteric bacteria in general. Furthermore, the 
assays were conducted through the pure culture of E. coli from the dog GI tract to avoid the 
confounding effect of IgG that is already bound on the bacteria surface. Moreover, isolates were 
acquired from healthy dogs and dogs with IBD in case the strains differed based on dog disease 
status. 
To isolate E. coli, fresh fecal samples from dogs with IBD and healthy dogs were diluted 
in PBS and homogenized using a vortex. The bacterial suspension was cultured in Tryptic Soy 
Broth (TSB) (BD, Franklin Lake, NJ, USA) at 37°C overnight with shaking. The overnight 
cultured suspension was plated on McConkey agar and incubated in aerobic conditions overnight 
at 37°C. The next day, the cultured colonies were assessed based on the colony morphology and 
appearance of agar color, and each E. coli-suspected colony was further subcultured onto blood 
agar as well as a parallel subculture on McConkey agar. The next day, the pure culture isolates 
were submitted to the CSU-VTH diagnostic lab to confirm the E. coli species. 
 
2.3.5 Macrophage isolation and culture 
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Blood from healthy dogs was processed for macrophage culture as previously described33. 
Briefly, peripheral blood mononuclear cells (PBMC) were separated from EDTA-anticoagulated 
blood samples by Ficoll-density gradient isolation; the PBMC were washed in PBS, resuspended 
in complete medium (DMEM, 1% Penicillin-streptomycin, essential and nonessential amino acid) 
with 1% FBS and plated at a density of 1x106 PBMC/0.5 ml in 48-well polystyrene cell culture 
plates, followed by incubation for 4 hours at 37°C. After allowing for monocyte adhesion, the non-
adherent cells were washed off with PBS twice, refed with complete medium with 15% FBS, 
supplemented with 10 ng/ml huM-CSF (Peprotech, Rocky Hill, NJ, USA) and cultured for 7 days. 
The culture medium was changed every 2 days. After 7 days in culture, the monocyte-derived 
macrophages were used to assess the macrophage activation, phagocytosis and cytokine assays 
following incubation with fecal bacteria derived from healthy dogs and dogs with IBD (described 
later). 
 
2.3.6 Macrophage phagocytosis and activation assays 
Ten fecal bacteria samples (5 samples per group; IBD and healthy) were used in the 
macrophage phagocytosis and activation assays. Note that the bacteria used in these assays were 
nonviable after being processed, frozen and stained with PI. The numbers of bacteria were counted 
using PI-labeled bacteria relative to a number of counting beads (Invitrogen, Eugene, OR). The 
final numbers of bacteria in the samples were calculated by comparing the ratio of the bead events 
to the bacterial cell events according to the manufacturer’s datasheet. To assess bacterial 
phagocytosis, the fecal bacteria at the MOI ratio of 5 bacteria per 1 macrophage were added to the 
macrophage cultures used. The bacteria were subsequently spun onto macrophages by 
centrifugation at 2000 x G for 10 minutes and incubated for 2 hours at 37°C. Nonphagocytosed 
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bacteria in the cultures were then washed, and the macrophage cells were detached and analyzed 
via flow cytometry analysis. The % of PI+ve macrophages and the PI abundance in macrophages 
were analyzed. 
To evaluate the activation of macrophages by fecal bacteria, macrophages were cultured, 
and this was followed by a phagocytosis assay; however, rather than detaching the cell to flow 
cytometry analysis at the end, the macrophages cultured were washed twice with PBS, refed with 
the new fresh media and cultured for an additional 24 hours. The supernatants were collected for 
cytokine (TNF-a and IL-10) measurement by ELISA. As a positive control for cytokine release 
and activation, 10 ng/ml LPS was added to parallel cultures of macrophages. These assays were 
repeated 3 times using blood from 3 different unrelated donor animals to ensure reproducibility. 
 
2.3.7 Flow sorting and 16S rRNA sequencing 
The fecal bacteria from 3 populations were analyzed for the bacterial subset composition 
using 16S rRNA sequencing and microbiome analysis. The 3 populations consisted of total fecal 
bacteria from dogs with IBD (n =10), fecal bacteria from healthy dogs (n=10), and bacteria with 
high levels of bound IgG (IgGhi bacteria) obtained from the feces of dogs with IBD (n = 10) 
following incubation with anti-dog IgG secondary antibody (as previously described) to enrich for 
IgG+ bacteria. The population of IgGhi bacteria (MFI greater than normal baseline) was sorted by 
the BD FACSAria sorter. The purity of the sorted product was assessed by flow cytometry and 
was found to consist of at least 85% IgGhi bacteria. The sorted population was compared to the 
IBD nonsorted population. The population not subjected to sorting (e.g., sorting IgG negative 
bacteria) was substantially less because nearly all bacteria in dogs with IBD were IgG+ve. 
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Bacteria were subjected to 16S rRNA sequencing following DNA extraction using a Mobio 
PowerSoil DNA Isolation kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. 
Extracted DNA was submitted for 16S rRNA sequencing and analyzed by Novogene Corporation 
(Chula Vista, CA). The 16S rRNA sequencing was performed as reported in a previous study34. 
Sequence analysis was performed using Uparse software (Uparse v7.0.1001 
http://drive5.com/uparse/)35. For each representative sequence, Mothur software was performed to 
compare results against the SSUrRNA database of the SILVA Database (http://www.arb-
silva.de/)36 for species annotation at each taxonomic rank (Threshold: 0.8~1). The OTU abundance 
data were normalized using a standard of the sequence number of the least sequence sample. 
Subsequent analyses of the alpha and beta diversity were performed based on these output 
normalized data. The alpha diversity was calculated using the Shannon diversity index. The beta 
diversities on both unweighted and weighted UniFrac were calculated by QIIME software 
(Version 1.7.0). 
 
2.3.8 Statistical analysis 
Data were analyzed using Prism 7 software (GraphPad, San Diego, CA, USA). The 
normality of the data was initially examined using the Shapiro-Wilk normality test. The normally 
distributed data were reported as the mean ± standard deviation (SD). Data that were not normally 
distributed were shown as the median (range). Statistical differences between the IBD and healthy 
dogs were analyzed using the two-tailed unpaired t-test for parametric data and Mann-Whitney 
test for nonparametric data as indicated in the text. For statistical analysis of the serum IgG 
response, the % IgG binding E. coli were compared using a one-way ANOVA. The results from 
repeated experiments, including cytokine production from different PBMC donors, were 
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standardized to the baseline control before analysis. To analyze the association between Ig-binding 
bacteria and other clinical variables, including the disease activity index and histopathology score, 
linear regression analysis was performed. The Receiver-Operating Characteristic (ROC) curve was 
calculated to determine the sensitivity and specificity as a diagnostic ability between IBD and 
normal dogs. The microbiome analysis was performed by the company as previously described. 




2.4.1 Breed characteristics of study dogs 
Twenty dogs diagnosed with IBD were enrolled in the study. All dogs showed clinical 
signs that matched the inclusion criteria as previously described. The demographic and health 
parameter data of the 20 dogs with IBD enrolled in the study were shown in Table 2.1 and 2.2. 
The breeds included mixed breeds (n=4), Bernese Mountain Dog (n=4), Yorkshire Terrier (n=2), 
Labrador Retriever (n=2), Rottweiler, Pug, Cavalier King Charles Spaniel, Boxer, German 
Shorthaired Pointer, American Eskimo, Siberian Husky, and English Bulldog. The breeds in the 
healthy control group (n = 9) included Standard Poodle, mixed breed dogs, Cocker Spaniel, Nova 
Scotia Duck Tolling Retriever, Shih Tsu, English Coonhound, English Setter, and Chihuahua. 
Overall, there was no significant difference in age between the healthy control dogs and dogs with 
IBD (p = 0.42). However, the body condition score in healthy dogs were greater than IBD dog (p 
= 0.01) which is the common finding since the IBD patients had thin body during episode of illness. 
In addition, the type of diet that each dog had during the study period was shown in Table 2.2 and 
2.3. For disease severity in IBD group, the disease duration was classified as chronic, with a 
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moderate disease activity index (Table 2.2). Briefly, eleven of the dogs with IBD had moderated 
lymphoplasmacytic inflammation of the duodenum, in 5 cases associated with mixed 
eosinophilic/neutrophilic infiltration. Six dogs had mild lymphoplasmacytic inflammation and a 
half of them were found to have mixed eosinophilic infiltration. Three cases were documented the 
severe lymphoplasmacytic inflammation and 2 of them were mixed infiltrates. Additional 
observations included glandular degeneration, crypt abscesses, lacteal dilatation, villous fusion 
and villous shortening. The evaluated score by endoscopic examination and WSAVA 
histopathology scores were also reported in Table 2.1 and 2.2.  
 
2.4.2 IgG binding to fecal bacteria in dogs with IBD versus healthy dogs 
The IBD dogs had an increased overall degree of the humoral immune response toward 
their gut bacteria compared to the healthy dogs. The percentage of IgG+ bacteria in the feces of the 
dogs with IBD was significantly greater than it was in the feces of the healthy control animals: 
IBD: 80% ± 15.05; healthy: 47.5% ± 18.35, p < 0.0001, (Figure 2.2A). Moreover, the overall 
amount of IgG bound by bacteria, assessed by the mean fluorescence intensity (MFI), was 
significantly higher in the dogs with IBD than in the healthy dogs (MFI-IBD: 11,769 ± 6,539 a.u.; 
MFI-healthy: 6,650 ± 2,687 a.u., p = 0.005, Figure 2.2B). The study indicated that there was a 
substantially higher percentage of IgA+ bacteria in the IBD dogs than in the healthy dogs; however, 
the magnitude of the degree difference was less than for IgG binding (IBD: 84.86% ± 9.87; healthy: 
73.18% ± 15.83, p = 0.022, Figure 2.2C). Nevertheless, there was no significant difference in the 
total IgA ligand binding with bacteria in both groups of dogs (MFI-IBD: 7,607 (2,834-17,120) 
a.u.; MFI-healthy: 7,113 (3,280-11,925) a.u., p = 0.91, Figure 2.2D).  
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We also used confocal microscopy to visualize the IgG+ and IgA+ populations of bacteria, 
as well as the potential overlap in the two populations, in the dogs with IBD and healthy dogs 
(Figure 2.3). The IgG+ bacteria were visualized in red with rabbit anti-dog IgG-Cy3 conjugate 
antibody, and the IgA+ bacteria were visualized in green with goat anti-dog IgA-FITC conjugated 
antibody. Bacteria expressing both immunoglobulins appeared yellow in merged images. The 
results indicated that there was a predominant population of the IgA+ bacteria in the feces of the 
healthy dogs, with substantially fewer IgG+ bacteria (Figure 2.3). In the case of the dogs with IBD, 
many more IgG+ bacteria were present, as reflected by a large number of dual positive (yellow) 
bacteria visualized. Linear regression analysis showed a significant correlation between the 
percentages of IgG+ and IgA+ bacteria in the dogs with IBD (R2=0.45, p = 0.001; Figure 2.4). A 
similar correlation of the MFI of IgG+ and IgA+ bacteria was also noted (R2=0.48, p = 0.001), 
which suggests that in IBD cases, increased IgG binding activity was associated with increased 
IgA binding in terms of both percentages of bacteria bound and in the abundance of IgG and IgA 
present on the surface of bacteria. However, there was no significant correlation between the IgG 
and IgA-binding activity found in healthy dogs. 
 
2.4.3 Recognition of fecal bacteria by circulating IgG    
To investigate whether the production of IgG bound to gut bacteria occurs primarily in the 
GI tract or whether it is alternatively produced in tissues of extraintestinal lymphoid and 
secondarily translocated to the GI tract (e.g., by leakage from intestinal vasculature), investigation 
assays using the serum and their IgG antibodies with specific binding to the common intestinal 
bacterium (E. coli) were performed as outlined in the methods. Note that because bacteria from 
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the GI tract of IBD dogs typically contained relatively high levels of IgG binding, these assays 
were performed using pure cultures of E. coli from the GI tract of dogs (total of 6 isolated strains). 
We determined that the quantity of the IgG found in the serum bound to E. coli did not 
differ between the dogs with IBD and healthy serum (Figure 2.5). Moreover, there were no 
differences in the recognition of serum IgG in the different isolated strains of E. coli from healthy 
dogs or dogs with IBD. For example, the percentage of serum IgG-binding E. coli was reported as 
the 4 following groups: 1) IBD serum vs. healthy E. coli: 51.54 ± 14.09%, 2) healthy serum vs. 
healthy E. coli: 49.12 ± 9.52%, 3) IBD serum vs. IBD E. coli: 44.47 ± 11.07%, and 4) healthy 
serum vs. IBD E. coli: 50.41 ± 9.86%. In addition, we also found the similar recognition of serum 
IgG toward Enterococcus strains as shown in Figure 2.6. Therefore, the study concluded that the 
production of IgG bound on the fecal bacteria surface occurs locally in the GI tract, instead of 
systemically. These results were also in agreement with the high levels of plasma cells found in 
the GI tract of IBD dogs that were previously discussed16, 17. 
 
2.4.4 Macrophage phagocytosis of fecal bacteria increased in dogs with IBD 
With the existence of a substantially high IgG+ bacteria level in the GI tracts of IBD dogs, 
we subsequently sought the potential links between this phenomenon and the induction of 
intestinal inflammation. One outstanding mechanism linking the GI inflammation and IgG+ 
bacteria is that the gut bacteria could involve an interaction with phagocytic cells, including 
macrophages in the lamina propria. Thus, an in vitro system was applied to identify whether gut 
bacteria from dogs with IBD were inherently more inflammatory than gut bacteria in healthy dogs. 
First, we compared the relative phagocytosis abilities of primary macrophages to 
phagocytose bacteria from health dogs versus IBD dogs (Figure 2.7). The fecal bacteria from dogs 
65 
 
with IBD significantly induced higher macrophage phagocytosis activity than the fecal bacteria 
from healthy dogs. For example, the percentage of macrophages containing phagocytosed bacteria 
was 67.91 ± 13.68% in cultures incubated with bacteria obtained from the IBD animals, compared 
to 55.05 ± 15.48% for bacteria obtained from the healthy dogs (p = 0.023, Figure 2.7B). 
Furthermore, the mean levels of ingested bacteria for each individual macrophage (reflected by 
MFI) was significantly high in the macrophages incubated with IBD bacteria (MFI: 2,994 (2,378-
3,912)) compared to healthy bacteria (MFI: 2,519 (2,323-3,428), p = 0.005, Figure 2.7C). 
Therefore, in dogs with IBD, GI bacteria are more likely phagocytosed through macrophages than 
healthy dogs’ bacteria, which suggests more efficient Fc-receptor mediated uptake of the heavily 
IgG-coated bacteria from dogs with IBD. 
 
2.4.5 Ingestion of bacteria from dogs with IBD triggers greater macrophage inflammatory 
response 
 Bacteria ingestion, primarily through Fc receptor-mediated internalization, functions as a 
critical stimulus of activating macrophages37. Thus, the next evaluation was related to how the 
phagocytosis of fecal bacteria influences the activation of macrophages and the production of 
cytokines. The study of activated macrophages by bacteria indicated that the expression of 
costimulatory molecules on macrophages was highly expressed costimulatory molecules (MHCII, 
CD40) approximately 80-100% of the total cells. However, no significant difference in the 
costimulatory molecule expressions was observed between activated macrophages incubated with 
bacteria from IBD and healthy dogs. Importantly, the incubation of macrophages with IBD fecal 
bacteria yielded higher levels of TNF-a production than the incubation of macrophages with fecal 
bacteria from healthy dogs (IBD; 332.3 ± 97.28 versus 234.1 ± 30.12 pg/ml, p = 0.04; Figure 2.8). 
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In contrast, the incubation of macrophages with IBD bacteria led to substantially lower IL-10 
(159.3 ± 12.8 pg/ml) than macrophages incubated with healthy dog bacteria (219.3 ± 51.52 pg/ml, 
p = 0.03). Therefore, we concluded that the gut bacteria found in the IBD dogs were integrally 
more likely to stimulate an inflammatory response than bacteria from the healthy gut, as shown by 
the capability of activating the production of pro-inflammatory cytokines, such as TNF-a, from 
activated macrophages. 
 
2.4.6 Microbiome analysis and selectivity of IgG binding 
Through sequencing of 16S rRNA metagenomics, the overall gut microbiome complexity 
and composition in dogs with IBD was compared to that of healthy dogs (Figure 2.9). In dogs with 
IBD, there was a greater relative abundance of bacteria in the Proteobacteria phylum (p = 0.045; 
Figure 2.10), including Escherichia-Shigella, and other genera, such as Clostridium, Blautia, 
Bifidobacterium, Enterococcus, Pseudomonas, Faecalibacterium, and Lactobacillus, together 
with a decreased relative abundance of Bacteroidetes phyla (p = 0.02) and additional genera, 
Streptococcus, Fusobacterium, Peptoclostridium, and Turicibacter, compared to the flora present 
in healthy control dogs (Figure 2.9A). These results are mainly in agreement with previous studies 
of the microbiome in dogs with IBD and indicate that our study populations were similar to those 
of other research regarding the diversity of bacteria and abundance difference of the gut 
microbiome in IBD versus healthy dogs38-40. 
Then, 16S rRNA sequencing studies were conducted to determine whether the increased 
levels of IgG binding on bacteria found in the feces of dogs with IBD identify exclusively enriched 
bacteria subsets (e.g., potentially pathogenic bacteria) or whether there was an even distribution in 
the population of IgGhi bacteria within all major phyla (i.e., no enrichment for specific phyla or 
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genera). The research rationale is the previous evidence for the selective binding of the 
immunoglobulin to pathogenic bacteria in CD patients21, 22. 
The bacteria that had the highest degrees of IgG binding were: Collinsella, Faecalitalea, 
Escherichia-Shigella, Blautia, Bifidobacterium, Clostridium innocuum, Slackia and Enterococcus 
(Figure 2.9A and Table 2.4). The taxa that had the smallest amount of IgG binding were 
Pseudomonas, Clostridium (sensu stricto) and Lactobacillus. According to this study, we found 
that the predominant fecal bacterial phyla present in the IgGhi bacterial populations were very 
similar overall to those of nonsorted bacteria from paired IBD samples with the exception that 
there was a significant enrichment of bacteria in the Actinobacteria phylum (p = 0.036) in the IgGhi 
population, compared to the nonsorted IBD bacteria (Figure 2.9B, 2.9C and Table 2.4). Moreover, 
the most abundant genus in this phylum was Collinsella, which was significantly enriched in the 
IgGhi sorted population of bacteria compared to the nonsorted bacteria. Therefore, these studies 
indicated that there was a preference in the immune recognition of Actinobacteria in dogs with 
IBD. 
 
2.4.7 Sensitivity and specificity of fecal bacteria IgG assay for the detection of IBD in dogs   
 The previous results indicated that the quantitation of the relative degree of IgG binding to 
fecal bacteria might be valuable as a diagnostic test for the detection of IBD in dogs. Thus, this 
study examined the specificity and sensitivity of the flow cytometric assay for IBD diagnosis in 
dogs, measuring both the percentage IgG+ bacteria and the quantity of IgG bound to each bacterial 
cell (i.e., MFI). Through receiver operating curves (ROC), it was determined that the area under 
the curve (AUC) for IgG+ bacteria was 0.92 (95% CI: 0.80-1.03, p < 0.0001; Figure 2.11). These 
findings showed that there was a high diagnostic ability for the flow cytometric test utilized with 
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respect to the percentage of IgG+ bacteria for distinguishing between healthy dogs and dogs with 
IBD. 
 We determined the sensitivity and specificity of the bacterial IgG assay through the cutoff 
point at the upper limit of the 95% confidence interval established using the range of percentage 
of healthy dogs, which was identified as 60% IgG+ bacteria. Using this cutoff, values of 85% 
sensitivity (95% CI: 62.11-96.79) and 89% specificity (95% CI: 51.75-99.72) were achieved for 
the detection of clinically apparent IBD in dogs, based on flow cytometric analysis of IgG binding 
to fecal bacteria. Overall, the fecal IgG test in dogs had a positive likelihood ratio of 7.727 and a 
negative likelihood ratio of 0.169. Thus, the test showing IgG+ bacteria above 60% (positive of the 
test) is moderate to highly suggestive of IBD. However, the IgG+ bacteria percentage did not 
correlate with the activity index of disease, including CIBDAI (p = 0.71) and CCECAI (p = 0.55). 
Furthermore, the overall endoscopic lesion scores and the histopathologic score had no relationship 
with the IgG+ bacteria percentage (p = 0.28 and p = 0.75, respectively), as determined by linear 
regression analysis. Thus, the assessment of IgG bound to the surface of bacteria was found to be 
a very sensitive and specific test for the detection of IBD in dogs, although the test positivity did 
not correlate with the disease activity or severity. Therefore, it was concluded that the fecal IgG 
assay had a higher specificity and sensitivity for the diagnosis of IBD than other currently available 
assays for detecting IBD in dogs, including fecal calprotectin (S100A12), which was found to be 






The interaction between the gut bacteria and the host immune response is currently 
considered a primary driver of intestinal inflammation in humans with IBD6-8. There is 
considerable evidence of a greater degree of IgG responses against gut bacteria in CD patients12, 
18, 19. For example, the abundance of IgG+ bacteria is shown to be specific for Crohn’s disease 
because increased IgG+ fecal bacteria levels are not found in patients with coeliac disease42 and 
infectious colitis12, 18. Similar studies have not previously been conducted in dogs with IBD and to 
the authors’ knowledge, this research is the first study that investigates an immune response against 
gut bacteria in this disease in the canine population.  
The key finding from this study is that dogs with IBD had a significantly higher binding of 
IgG to gut bacteria than healthy dogs (Figure 2.2). For example, in IBD dogs in general, there was 
30% more bacteria bound with IgG than there were in healthy dogs (Figure 2.2A). The numbers 
are roughly in agreement with the results of the IgG binding bacteria previously described for UC 
and CD patients12, 18. In addition, we further evaluated the IgG-binding in patients with giardia 
infection represented the model for infectious GI disease. As expected, the % IgG-binding to gut 
bacteria was lesser than the level found in IBD (p = 0.0002; Figure 2.13) and comparable to the 
degree from normal dog. This result agreed with a report from infectious colitis study18 and 
suggested that the lesser immune response reacted to gut bacteria in case of GI infectious disease. 
Furthermore, this study also indicates that the anti-bacterial IgG production sources were more 
likely from local immunoglobulin in the gut instead of systemically released by extraintestinal 
locations, which is also reported in the investigation of patients with Crohn’s disease7, 12. Thus, the 
fecal IgG test would be the potential test indicating the degree of local immunity reaction to gut 
bacteria which is specific for IBD pathogenesis.   
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One difference between the immunoglobulin responses against gut bacteria in our study 
and studies in CD is that there was no heightened IgA ligand binding to bacteria in IBD dogs, 
while humans exhibited substantially high IgA ligand abundance presented on gut bacteria 
compared to gut bacteria in healthy patients12. The reasons for this variation are unclear; however, 
it is important to note that the concentration of soluble IgA was reported to be generally lower in 
the feces of IBD dogs than in healthy dogs13, 43. 
 This study also shows a plausible connection between bacterial IgG binding and the 
induction of intestinal inflammation, which could entail macrophage activation in the gut. For 
example, the study indicated that macrophage incubation with fecal bacteria from dogs with IBD 
significantly increased the production of TNF-a and the activation of macrophages than bacteria 
obtained from the GI tracts of healthy dogs (Figure 2.7, 2.8). In contrast, bacteria from dogs with 
IBD caused a significantly lower production of IL-10 through macrophages than those from 
healthy dogs. Therefore, the net impact of the macrophage interactions with IgG bound bacteria in 
IBD animals could be the activation of increased local inflammation and immune activation. This 
impact could have interceded, in part, through the interaction of IgG-binding bacteria with 
triggering Fc receptor activation through macrophages found in the lamina propria or intestinal 
epithelium43, 44. 
 Interestingly, we found that the IgG response against the gut bacteria in dogs with IBD 
appeared to be directed preferentially toward bacterial groups considered parts of the dysbiotic 
flora, as described in previous studies24, 25, 38-40. Moreover, we found that bacteria in the genera 
Collinsella had the most preferential recognized IgG in dogs with IBD, whereas this organism did 
not express greater IgG binding in healthy dogs (Figure 2.9A and Table 2.4). Interestingly, this 
genus was noted in dogs with gastric-dilation and volvulus45 and has also been reported to be one 
71 
 
of the high IgA binding bacteria detected in patients with CD11, 46. While not all dysbiotic flora are 
considered pathogenic, some of the genera found in dysbiosis (e.g., Escherichia, Clostridium and 
Enterococcus) have been associated with intestinal infection and invasion47-50. These 
enteroinvasive pathogenic bacteria could trigger greater immune recognition and local antibody 
production50-52. 
In terms of diagnostic utility, our studies demonstrated that a bacterial flow cytometric IgG 
assay using fecal samples provided significant sensitivity and specificity to distinguish dogs with 
IBD from healthy dogs (Figure 2.11). As there is no commercially available assay for accurately 
identifying dogs with IBD, this bacterial flow cytometric assay may provide a useful and relatively 
straightforward assay that can be conducted on fresh or frozen fecal samples. For example, we 
found that the fecal IgG-binding bacteria assay provided consistent results whether the samples 
were stored at -20°C or -80°C (coefficient of variation = 19.27%). 
Our findings did not show an association between the degree of IgG+ bacteria and clinical 
parameters associated with IBD, including the disease activity index, the histopathology score, and 
the endoscopic score. Similar to previous IBD studies in dogs, the clinical parameters showed a 
lack or weak correlation with other IBD parameters, including serum Ig, C-reactive protein and 
Calprotectin13, 53, 54. 
 However, the relative abundance of the genus Collinsella, which was found to have the 
highest IgG binding in dogs with IBD (Figure 2.9C), showed the highest association with standard 
IBD clinical parameters, including CCECAI (p = 0.024), CIBDAI (p = 0.032), histopathology 
scores (p = 0.016) and serum folate concentrations (p = 0.008, Figure 2.12). This finding was in 
agreement with previous studies in humans and cats46, 55. In humans, Collinsella is considered one 
of the taxa used to differentiate between patients with UC and CD46. Fusobacterium and 
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Clostridiaceae were also reported to be associated with CIBDAI in dogs25, 38; however, in the 
present study, no association with these taxa and IBD was observed. 
Through a culture-independent technique of 16S rRNA metagenomic sequencing for 
microbiome analysis, this investigation shows a relatively good correspondence to the previous 
sequencing studies on dogs with IBD focused on mucosa-associated or fecal microbiota24, 25, 38-40. 
For example, a previous study reported dysbiosis of commensal bacteria, including increased 
Proteobacteria (e.g., E. coli), Clostridium, and Enterococcus40. In addition, our study extensively 
identified that these dysbiotic bacteria presented with a high degree of IgG already attached on 
their surface (Figure 2.9A), leading to a greater overall percentage and increased MFI of IgG-
binding bacteria in dogs with IBD (Figure 2.2). However, some of the high IgG binding taxa 
determined in this study were considered to be non-IBD related taxa in previous studies on IBD 
dogs, including Faecalibacterium, Allobaculum, Slackia and Clostridium39.   
In our setting, the average age was middle-aged dogs corresponding to the common age 
for having IBD56 and was not different from healthy controls, which minimized a potential 
alteration of the immune response by age57. The healthy controls were client-owned dogs (not a 
laboratory setting) with various home environments and diets. Thus, they were justified as pet dog 
representatives. As a different diet potentially influences the microbiome, we also reported the 
type of diet that each dog had during the study period (Table 2.2, 2.3). Although a variety of diets 
was documented in both groups, the microbiome changing was found to agree with other IBD 
studies38-40 suggesting altered microbiome was primary influenced by causative disease rather than 
diet. In addition, we were unable to breed-matched them with the IBD group because of the small 
number of controls. One potential limitation of this study is that some dogs with IBD had 
undergone an antibiotic intervention before they were enrolled in the study. Antibiotic treatment 
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is known to significantly change the intestinal microbiome in dogs58, 59. Nevertheless, there were 
no substantial changes in the IgG+ bacteria percentage in the dogs despite their history of antibiotic 
pretreatment, which implies that there is a minimal discernable effect of antibiotic treatment on 
the production and function of anti-bacterial IgG in dogs with IBD. This observation is crucial 
because it indicates that a fecal IgG assay could be moderately resistant to the potential influence 
of past antimicrobial therapy. 
This study demonstrates that a greater percentage of intestinal bacteria were recognized 
through local IgG produced in the gut of dogs with IBD and that IgG bound bacteria may be 
relevant to intestinal inflammation. These outcomes must be proven through more extensive 
studies in dogs with IBD and compared to animals with other causes for GI dysfunction, such as 
viral infection, dietary changes, and infections with GI parasites (e.g., hookworm, whipworm, or 
Giardia infection; preliminary result shown in Figure 2.13). Furthermore, the analysis of the serial 
samples at a later stage after treatment at the various follow-up time points could also be beneficial. 
These studies could provide additional insights into the role of local gut immune responses against 
bacteria and the potential role of these processes in mediating GI inflammation in a variety of 




This study demonstrated that the gut bacteria found in IBD dogs had a substantially greater 
degree of IgG binding than gut bacteria in the healthy dogs. In addition, the highest level of IgG 
binding appeared to be directed against certain phyla of dysbiotic bacteria, with significant high 
preference for Actinobacteria.  Furthermore, IgG coated bacteria from IBD dogs significantly 
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activated higher production of TNF-a by macrophage than bacteria derived from the healthy 
indicative of the inherently pro-inflammatory effect of high IgG binding to bacteria.  These 
findings suggest that humoral immune recognition of endogenous intestinal bacteria may be an 
important mediator causing intestinal inflammation in dogs with IBD linking as a crucial part in 




Figure 2.1 Flow cytometry analysis and gating. Fecal bacteria were analyzed based on size and 
complexity corresponding to bacteria population as well as selective counting of 105 bacteria cells. 
The percentage of positive fluorescence cells of IgG-binding bacteria and fluorescence intensity 




Table 2.1 Summary demographic data of study groups.  
 IBD Normal 
Sample size 20 9 







Age (year) 6.4 ± 3.77 7.6 ± 3.05 
Weight (kg) 24.04 ± 13.79 22.73 ± 11.35 
BCS (9 scales) 4.1 ± 1.13 5.33 ± 0.86 
Disease Duration (month) 4.62 ± 5.27 - 
Disease activity index   
 -CIBDAI 
 -CCECAI 
6.7 ± 3.57 
8.1 ± 4.55 
NP 
Endoscopic lesion 100% NP 
Endoscopic score   
 -Gastroscopic 
 -Duodenoscopic 





WSAVA Histopathology score  5.15 ± 2.68 NP 
Data reported as Mean ± SD and Median (range).  
CIBDAI = Canine Inflammatory Bowel Disease Activity Index; CCECAI = Canine Chronic 
Enteropathy Clinical Activity Index; NP = not performed. 
 
 
Table 2.2 Demographic data, diet and histopathologic evaluation of IBD group.  
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6 4 7 9 Any food if 
dog eats 
Mild lymphoplasmacytic 
and suppurative enteritis 
with some eosinophils 
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1. Duodenum: Moderate 
lymphoplasmacytic and 
eosinophilic enteritis.  
2. Ileum: Mild 
lymphoplasmacytic and 


















active, moderate with 
crypt abscesses, mild 











3. Colonic inflammation, 
lymphoplasmacytic and 
eosinophilic, chronic, 
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1. Duodenum: Enteritis, 
lymphoplasmacytic, 
chronic, moderate with 




severe with villus fusion  
3. Colitis, 
lymphoplasmacytic, 
chronic, mild with 









1. Severe catarrhal 
enteritis in duodenum 
and ileum, with bacterial 
colonies on the surface 
2. Duodenum, Ileum: 
increased lymphocytes 
and plasma cells 
throughout the lamina 













with mild villus 
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of crypt abscesses 
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lymphoplasmacytic 
enteritis with glandular 
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enterocolitis, few crypt 












1. Duodenum: Moderate 
lymphoplasmacytic 
enteritis with few 
neutrophils and 
moderate to marked 
intraepithelial 
lymphocytes infiltration. 
2. Ileum: Minimal 
lymphoplasmacytic 
enteritis with mild 
intraepithelial 
lymphocyte infiltration.  












1. Duodenum: Moderate 
lymphoplasmacytic 
duodenitis 
2. Ileum: minimal 
presence of lymphocytes 
and plasma cells within 
the lamina propria 
3. Colon: Mild 
lymphoplasmacytic and 














1. Duodenum: Moderate, 
diffuse, chronic, 
lymphoplasmacytic 
enteritis with moderate 
villous blunting 









         
 
Table 2.3. Demographic data, and diet of normal group.  





1  English Setter 9 5 Commercial dog food with venison 
2  English 
Coonhound 
12 7 Commercial dog food; weight control formula 
3  Mixed breed 6 5 Commercial dog food; standard formula 
4  Mixed breed 9 6 Commercial dog food; senior formula  
5  Cocker Spaniel 5 5 Commercial dog food; standard formula 
6  Standard Poodle 6 5 Commercial dog food; standard formula 
7  Nova Scotia 
Duck Tolling 
Retriever 
5 5 Commercial dog food with lamb and rice 
8  Chihuahua 12 4 Commercial canned dog food with venison 
9  Shi Tsu 4 6 Commercial dog food; standard formula 








Figure 2.2 IgG+ and IgA+ fecal bacteria in healthy dogs and dogs with IBD. (A) The 
percentages of IgG+ bacteria are plotted in dogs with IBD versus healthy dogs.  (B) The amount 
of IgG bound to each bacterium (MFI) is plotted for the two groups of animals.  IgA binding 
percentages and total IgA binding to each bacterium are depicted in C and D, respectively. Data 
are plotted as Mean ± SD. Statistical differences were calculated using two-tailed unpaired t-test 




Figure 2.3 Ig-binding fecal bacteria. Immunofluorescence staining and imaging of fecal bacteria 
from a healthy dog (top row) and from a dog with IBD (bottom row).  IgA bound to bacteria 
indicated as green, while IgG+ bacteria indicated as red.  Bacteria with both bound antibodies show 
up as yellow images in merged figures.  Scale bar indicates 10 µm. 
 
 
Figure 2.4 Association between IgG and IgA binding to fecal bacteria.  Scatter dot plot of (A), 
percentage of IgA-bound and IgG-bound bacteria and (B) amount of IgG and IgA binding to 
individual bacteria (MFI) depicted. To analyze the degree of association between IgG and IgA 
binding, linear regression analysis was performed. The percentage of IgA-bound bacteria was 
significant correlated with the percentage of IgG-bound bacteria (R2 = 0.45, p = 0.001). Also, 
degree of IgA and IgG binding also showed significant correlation (R2 = 0.48, p = 0.001). Dashed 




Figure 2.5 Serum IgG recognition of E. coli isolated from healthy dogs and dogs with IBD. 
Six separate fecal isolates of E. coli (3 from dogs with IBD and 3 from healthy dogs) were 
incubated with serum from dogs with IBD (n=20) and healthy dogs (n = 9), and IgG binding to the 
surface of bacteria was quantitated using flow cytometry, as noted in Methods.  Scatter plots 
depicting IgG+ bacteria percentages in healthy versus IBD dogs plotted.  The percentages of IgG+ 
bacteria were not significantly different between the two groups of animal sera (p = 0.29).  (†) 
Indicates E. coli isolates from normal dogs, while (‡) indicates E. coli isolates from dogs with IBD.  
Data reported as Mean ± SD and statistical differences were calculated using one-way ANOVA. 
 
 
Figure 2.6 Serum IgG recognition of Enterococcus isolated from healthy dogs and dogs with 
IBD. Two separate fecal isolates of Enterococcus spp. (from dog with IBD and healthy dog) were 
incubated with serum from dogs with IBD (n=20) and healthy dogs (n = 9), and IgG binding to the 
surface of bacteria was quantitated using flow cytometry, as noted in Methods.  Scatter plots 
depicting IgG+ bacteria percentages in healthy versus IBD dogs plotted.  The percentages of IgG+ 
bacteria were not significantly different between the two groups of animal sera.  (†) Indicates 
Enterococcus isolated from normal dog, while (‡) indicates an isolate from dog with IBD.  Data 





Figure 2.7 Macrophage phagocytosis of fecal bacteria from dogs with IBD versus healthy 
dogs. (A) Fecal bacteria (PI staining; red) from dogs with IBD and from healthy dogs (n=5 per 
group) were incubated with primary cultures of canine monocyte-derived macrophages and 
bacterial uptake was determined using flow cytometry, as described in Methods.  Images were 
obtained using confocal microscopy, with PI stained bacteria visualized as red objects within 
cultured macrophages.  DAPI staining (blue) demonstrates cell nuclei. Similar results were 
obtained in at least n=3 repeated, independent studies.  Box plot comparing the percentage of 
macrophages containing intracellular bacteria (B) and the relative number of bacteria per 
macrophage (C), when bacteria from dogs with IBD and healthy control dogs were compared. 
Statistical differences were calculated using two-tailed unpaired t-tests (B) and by the Mann-






Figure 2.8 Cytokine production by activated macrophages.  Canine monocyte-derived 
macrophages were activated by incubation and phagocytosis of non-viable fecal bacteria obtained 
from dogs with IBD (n=5) and from healthy normal dogs (n=5), as described in Methods. TNF-a 
and IL-10 concentrations in media obtained from macrophage cultures 24 hours after bacterial 
inoculation were measured using commercial canine-specific ELISA. Box plots comparing 
cytokine concentrations between the 2 groups of fecal bacterial samples are depicted. Statistical 
differences were calculated using two-tailed unpaired t-tests. The assays were repeated for 3 times, 




Figure 2.9 Microbiome analysis. IgGhi sorted fecal bacteria from (n=10) dogs with IBD, and non-
sorted bacteria (n=10; paired fecal samples from dogs with IBD) and bacteria from healthy control 
animals (n=10) were analyzed by 16S rRNA sequencing, as described in Methods.  (A) Species 
abundance heat map at taxonomic level representing average differences, with 0 = no difference, 
-1 and 1 representing maximum differences.  (†) Showing the top 10 taxa abundance. (B) Bar 
graph depicting the relative abundance of 5 major phyla comparing the IgGhi sorted population 
with non-sorted bacteria, obtained from same dogs with IBD. A significant increased abundance 
of Actinobacteria phyla was found in IgGhi sorted population. (C) Bar graph showed relative 
abundance comparing between IgGhi sorted and non-sorted bacteria for members of Actinobacteria 
phyla. The data were reported as Mean ± SD, and statistical comparisons were calculated using 







Figure 2.10 Relative abundance of 5 major phyla in dogs with IBD and healthy controls.  
Significant decrease in Bacteroidetes (p = 0.02) and increased Proteobacteria (p = 0.045) were 
observed in dogs with IBD. Bar graphs depict relative abundance of 5 phyla, and statistical 















     Bifidobacteria 
     Slackia 
     Collinsella 
17.95 ± 11.08 
0.3 (14.4) 
0.38 ± 0.36 
15.1 ± 10.66 
12.23 ± 9.363 
0.25 (5.8)  
0.26 ± 0.21 






     Bacteroides 
     Prevotella 
2.38 ± 1.82 
1.08 ± 0.77 
0.34 (2.74) 
6.64 ± 4.07 






     Lachnoclostridium 
     Megamonas 
     Faecalitalia 
     Catenibacterium 
     Clostridium sensu stricto 
     Blautia 
     Enterococcus 
     Streptococcus 
     Clostridium innoculum 
     Lactobacillus 
     Erysipelotrichaceae 
     Turicibacter 
     Peptoclostridium 
     Erysipelatoclostridium 
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Table reported the comparison of % relative abundance between IgGhi-sorted and non-sorted 
bacteria from IBD group. Data shown in Mean ± SD (if parametric data) and Median (range) (if 
non-parametric data). The appropriate statistical comparison of 2 groups either paired t-test and 






Figure 2.11 Receiver operator curves for bacterial IgG assay. To quantify the diagnostic ability 
of the bacterial IgG assay to discriminate dogs with IBD (n=20) from normal dogs (n=9) based on 
percentage IgG-binding gut bacteria, ROC curve analysis was performed. Area under the curve 





Figure 2.12 Association of Collinsella and clinical parameters in IBD. Scatter dot plot of % 
abundance of Collinsella and clinical parameters depicted. Linear regression analysis was 
performed. The p value as stated in the figures. Dashed lines depict 95% confidence band. 
CIBDAI; Canine Inflammatory Bowel Disease Activity Index, CCECAI; Canine Chronic 






Figure 2.13 IgG+ fecal bacteria in Giardia+ve fecal samples. (A) The percentages of IgG+ 
bacteria are plotted in dogs with IBD, Giardiasis and healthy dogs.  (B) The amount of IgG bound 
to each bacterium (MFI) is plotted in groups respectively. Data are plotted as Mean ± SD. 
Statistical differences were calculated using One-way ANOVA with Tukey’s adjustment (*p ≤ 
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CHAPTER 3: MESENCHYMAL STEM CELLS (MSC) DERIVED FROM INDUCED 
PLURIPOTENT STEM CELLS (IPSC) EQUIVALENT TO ADIPOSE‐DERIVED MSC IN 
PROMOTING INTESTINAL HEALING AND MICROBIOME NORMALIZATION IN 





Background: The typical MSC therapy that exerts an immunomodulatory effect for suppressing 
gut inflammation has been evaluated in rodent models of IBD, as well as in clinical trials in humans 
and animals. Recently, iPSC-derived MSCs (iMSCs) have been suggested to be equivalent to 
conventional MSCs for the treatment of several inflammatory diseases. However, they have not 
been studied in IBD. 
Objective: The aim was to investigate the effectiveness of using iMSCs and conventional adipose-
derived MSCs (adMSCs) for the treatment of IBD in a mouse model of DSS-induced colitis. The 
comprehensive investigations included the effect of MSCs on inflammatory suppression, intestinal 
healing and microbiome alteration. We hypothesized that iMSCs and conventional cells are 
equally effective in ameliorating inflammation and supporting gut healing by tissue regeneration 
and microbiome restoration. 
Methods: Colitis was induced in mice via treatment with a chemical compound, and the mice 
received intravenous administration of iMSCs or adMSCs for 3 injections with a 2-day interval. 
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The effect of the treatment was assessed using the clinical score, histopathology, 
immunohistochemistry, and microbiome study, and the stem cell treatments were compared to the 
group of colitis with no treatment. 
Results: The iMSC and adMSC treatment effects were equivalent on the basis of significantly 
improving clinical abnormalities and decreasing inflammation inside the gut. iMSC administration 
also stimulated a substantial increase in intestinal epithelial cell proliferation, which was 
augmented in the Lgr5+ intestinal stem cells and amplified intestinal angiogenesis. Furthermore, 
the restored microbiome found in mice treated with adMSCs or iMSCs closely resembled those of 
healthy mice. 
Conclusion: The administration of iMSCs enhanced the overall intestinal healing and suppressed 
inflammation with equal effectiveness as treatment using adMSCs in a mouse model of colitis. 
This study is also the first report of iMSC effectiveness in IBD treatment and the first description 
of a unique mechanism of the action concerning microbiome restoration and intestinal healing.  
 This chapter includes the complete published manuscript1 for this aim. My contribution to 
this publication included study design, performing assay and mouse model study, data collection, 




Inflammatory bowel disease (IBD) in humans, including Crohn’s disease (CD) and  
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ulcerative colitis (UC), are the results of intestinal inflammation due to an abnormal immune 
response in the gut1-4. These diseases exhibit the following characteristics: inflammatory cell 
infiltration (activated T cells, neutrophils, monocytes, and macrophages), variable degrees of 
intestinal injury and occasionally ulceration5. Although there has been substantial progress in 
treating IBD using novel immunomodulatory medicines, there is a necessity for a new approach 
to the management and treatment of IBD, particularly treatments that have a long action duration 
and a small number of adverse effects. 
Cell-based therapy with mesenchymal stem cells (MSC) that utilizes their 
immunomodulatory effects has been a new promising therapeutic strategy for managing IBD. 
First, mesenchymal stem cells are strong immune regulators by suppressing several different 
inflammatory processes6-10. Significantly, it has been shown in a number of current studies in IBD 
rodent models that systemic MSC administration via i.p. or i.v. routes resulted in considerably 
improved intestinal inflammation11-14. Furthermore, these beneficial effects of systemic MSC 
application have been noted in individuals suffering from CD and UC treated with cellular therapy, 
as well as in a canine spontaneous IBD model15-21. Thus, there is robust evidence that MSC therapy 
is likely to be a practical option, even in individuals suffering from drug-refractory IBD. 
Although there is convincing evidence of the MSC therapy effectiveness in the 
management of IBD, our understanding of the mechanisms through which MSC regulates the 
immunological response and improve clinical abnormalities in the disease remains inadequate. For 
example, rodent models of IBD (principally the dextran sodium sulfate (DSS)-induced colitis 
model) have proven that the administration of MSCs can lessen neutrophil, T cell, and macrophage 
infiltrates and promote the regulatory T gut influx in the gut13, 22-24. There are contradictory data 
on the exact quantity to which MSCs essentially infiltrate to the gut after intravenous delivery, 
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although the consensus appears to be that general recruitment to the local area in the gut is fairly 
incompetent13, 25, 26. Currently, in IBD, most MSC therapy studies have concentrated on the 
immunomodulatory effect of MSCs. However, the findings from radiation-induced GI injury 
models suggest that MSCs may also have a trophic and stimulatory effect on the gut epithelium 
itself, such as the stimulation of intestinal stem cell proliferation27-29.   
 Nevertheless, despite the advantageous MSC therapies, challenges persist in the cellular 
therapy application as a practical option for IBD management. For example, the MSC source 
(whether autologous or allogeneic) is the primary variable that affects the therapeutic 
effectiveness30-32. Convincing data indicate that allogeneic MSCs are fully practical in IBD 
models, and there is significant evidence indicating that MSCs derived from young-aged donors 
are more immunologically active32-34. However, with the use of allogeneic donor MSCs, there is 
considerable donor-to-donor variability in MSC yields and functionality35, 36. Therefore, the 
regular use of MSC therapy with consistent effectiveness would be derived from a uniform cell 
source with a stable function and phenotype. 
 One potential way to solve this problem of a uniform cell origin is to use MSCs derived 
from induced pluripotent stem cells (iPSCs). Many studies have demonstrated that MSCs derived 
from iPSCs are similar to the conventional MSCs derived from adipose-tissue or bone marrow 
regarding both phenotype and function37-40. The iPSC-derived MSCs have shown their ability to 
suppress inflammation in vivo in mouse models with an allergic airway disease38, 40, 41. 
 Therefore, in the current study, we examined the iPSC-derived MSC (iMSC) effectiveness 
for IBD treatment, using a DSS-induced colitis mouse model. Studies were carried out to 
thoroughly examine the ways by which MSCs may ameliorate the intestinal abnormalities in IBD, 
including the effects on reduced inflammation, enhanced intestinal healing and restored 
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microbiome populations. The studies demonstrated that iMSCs were comparably effective to 
conventional, adipose-derived MSC for the treatment of established and ongoing colitis in mice. 
Furthermore, these studies also indicated significant indirect trophic effects of MSCs on 
angiogenesis, intestinal healing, and intestinal microbiome normalization. Overall, the studies 
provide strong support for the use of iPSC-derived MSCs as a more homogenous and sustainable 
source of cells for the cellular therapy of IBD.  
 
3.3 Materials and Methods 
 
3.3.1 MSC isolation, culture and tri-lineage differentiation 
The MSCs used for this research were isolated and obtained from inguinal and abdominal 
adipose tissues of 10 week old female CD-1 mice under sterile procedures. Approximately 0.5 
grams of fat tissue was cleaned with sterile DPBS (Dulbecco’s phosphate-buffered saline; Sigma 
Aldrich, St. Louis, MO), mechanically chopped using a scalpel and digested by collagenase (Sigma 
Aldrich; 1 mg/ml) for a period of 30 minutes at a temperature of 37°C. The stromal vascular 
fraction (SVF) was isolated by centrifugation at 380 g for a duration of 5 minutes. After washing 
twice with complete culture medium, the SVF was transferred into 75 cm2 tissue culture flasks 
(Falcon®, Thermo Fisher, Waltham, MA) and incubated at 37°C, 5% CO2. After 72 hours, the 
tissue culture flasks were washed to remove non-adherent cells and were refed with fresh complete 
medium. Proliferating colonies of adherent cells were allowed to grow to reach 70% confluency, 
with medium changes every 48 hours. The cells were subsequently detached from flasks for 
passage by treatment with trypsin (0.25% trypsin; EDTA, Gibco, Carlsbad, CA) and placed in 225 
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cm2 flasks for further growth. For the studies described here, adipose-derived MSC (adMSC) were 
used at passage 3 to 4 and collected when they were approximately 80% confluent. 
The iMSC line used in these studies was generated from a CD-1 mouse by the Colorado 
Denver Charles C. Gates University, Center for Regenerative Medicine and Stem Cell Biology 
iPSC Core. Transgene integration-free iPS cells were produced from mouse skin fibroblasts via 
the use of a CytoTune iPS Reprograming kit (Life Technologies Corp., Grand Island, NY) based 
on the manufacturer’s instructions. The capability of adipose-derived iMSCs and MSCs to undergo 
tri-lineage differentiation was evaluated using a StemPro® differentiation kit (Gibco). The 
differentiated cell phenotype was assessed by specific cytostaining (adipogenesis: Oil Red O; 
chondrogenesis: Alcian Blue; and osteogenesis: Alizarin Red). 
 
3.3.2 Flow cytometry 
The phenotypic evaluation of adMSCs and iMSCs was performed as previously described. 
Briefly, the single cell suspensions were prepared at 1x106 cells/ml in FACS buffer, and 1 X 105 
cells were immunostained in single wells of round bottom 96-well plates. The following antibodies 
(obtained from San Diego, CA) were used to immunostain the cells: Sca-1-APC (clone eBR2a), 
CD11b- FITC (clone M1/70), CD29-biotin (clone HMb1-1), CD31-FITC (clone 390), CD44-FITC 
(clone IM7), CD45-PE (clone 30-F11), CD73-PE (clone eBioTY/11.8), CD90.2-eFlour 450 (clone 
53-2.1), and CD106-biotin (clone 429). 
For the evaluation of leukocyte populations, the following primary antibodies were used: 
CD4-FITC (clone GK1.5), CD8-APC-e780 (clone 53-6.7), CD11c- FITC (clone N418), CD45-
eFlour450 (clone 30-F11), FOXP3-PE (clone JFK-16s), B220-APC (RA3-682), Ly6G-APC-e780 
(clone RB6-8C5), Ly6C-PE (clone HK1.4), and F4/80-APC (clone BM8). Furthermore, after 
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surface staining was performed, cells were processed for fixation and permeabilization for 
intracellular staining of anti-FOXP3 antibody. Cells were examined using a Beckman Coulter 
Gallios flow cytometer (Brea, CA), and data were analyzed using FlowJo Software (Ashland, OR). 
An example of the gating scheme is shown in Figure 3.1. 
 
3.3.3 DSS-induced colitis model and clinical scoring of disease severity 
Mice were induced to have intestinal inflammation via DSS (DSS; Mr ~40,000, Sigma-
Aldrich, St. Louis, MO) administered at a 2.5% w/v concentration in the drinking water, as 
previously described42. The amount of drinking water consumed was monitored, and fresh DSS 
was regularly prepared and changed every 2 days. DSS was administered in the water throughout 
the study period.  
For every study, mice (n = 5 per group) were randomly allocated to the following groups: 
1) untreated control group; 2) DSS + adMSC administration; 3) DSS treatment only; and 4) DSS 
+ iMSC administration. The mice were observed on a daily basis for clinical signs, body weight, 
stool color, and stool consistency. On days 10, 13 and 16 of the study (with DSS administration 
initiated on day 0), the administration of MSCs was performed via tail vein injection of 1x106 cells 
per mouse in 200 µl PBS. The control mice (group 1) and DSS only mice (group 3) were 
administered 200 µl of PBS via tail vein injection. 
Clinical scoring was performed with the use of a modified scoring matrix from previous 
publications13, 43. Concisely, the mice were weighed, and stool was collected daily; the mice were 
also observed daily for clinical signs. The % weight loss was calculated on a daily basis and scored 
as 0 (no loss), -1 (1-5%), -2 (5-10%), -3 (10-20%) and -4 for greater than 20%. The measure of 
the fecal occult blood was performed by a test kit (Fisher Healthcare, Houston, TX). A 
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modification of the color reference guide was employed to quantitate the positive occult blood 
level in a range of 0 (no blood), -1, -2, -3 and -4 with the darkest blue showing the strongest test 
kit positive reference color. The fecal consistency score was noted as follows; 0 (normal), -1 
(moist), -2 (loose stool), and -3 (watery). The final clinical score was the totality of the scoring 
from the fecal color, weight, and fecal consistency, and the maximum possible score was -12. 
 
3.3.4 Sample collection for histology and immunofluorescent staining   
At 19 days after DSS (3 days after the last MSC injection), the mice were euthanized, and 
the colon was collected, weighed and measured for the length. A colonic tissue section of 1 cm-
long was rapidly frozen at -80°C. One half of the remaining colon was fixed in 10% neutral buffer 
formalin for processing histology with H&E staining, and the other half was fixed in 1% 
paraformaldehyde-lysine-periodate (PLP) solution (1% paraformaldehyde in 0.2 M lysine-HCl, 
0.1 M anhydrous dibasic sodium phosphate, with 0.21% sodium periodate) for 24 hours at 4°C for 
immunohistochemical staining. After PLP fixation, the tissue was transferred in a 30% w/v sucrose 
solution for an additional 24 hours at 4°C, prior to embedding and freezing in O.C.T. compound 
(Tissue Tek®, Tokyo). 
 
3.3.5 Histopathology 
 Formalin-fixed paraffin embedded colon tissues were stained routinely with H&E staining 
for histological assessment. The evaluation of the colonic tissue histopathological scoring was 
performed in a blinded fashion by a board-certified veterinary pathologist. A previously published 
scoring system44 for colonic inflammation was modified to include a category for mucosal 
inflammation (score 1-6; 2 categories) and damage score (score 1-3) as follows: 1 (leukocyte 
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infiltration), 2 (mucosal erosion/ulceration +/- colonic gland ectasia and necrosis), and 3 (collapse 
of mucosal architecture +/- replacement granulation tissue). The final score was the sum of all 
scoring indexes, with a maximum possible score of 9. 
 
3.3.6 Immunofluorescence staining 
 For immunofluorescence staining, OCT-embedded frozen tissues were sliced at a 5 µm 
thickness and mounted on Superfrost slides (Fisher Scientific, Hampton, NH). The following 
primary antibodies were used: CD3 (clone 145-2C11), F4/80 (clone BM8), CD11b (clone M1/70), 
CD103 (clone 2E7), CD4 (clone 4SM95; all from eBiocience), CD31 (clone MEC 13.3; BD 
Pharmingen), cytokeratin-20 (Abcam, Cambridge, MA), FOXP3 (clone JFK-16s), Lgr5 (Abcam), 
and Ki-67 (clone SolA15; eBioscience); 0.1% Triton X and 0.25% saponin were employed as the 
permeabilizing agents, with overnight incubation at 4°C. The secondary antibodies were 
conjugated with Alexa Flour®488 or Cy3 (dilution 1:200 in PBST, Jackson ImmunoResearch 
Laboratories). The tissue sections were washed twice and counterstained with DAPI (Molecular 
Probe, Eugene, OR). The slices were subsequently mounted with Prolong® Diamond Antifade 
medium (Thermo Fisher, Waltham, MA) and placed with a coverslip. Appropriate isotype controls 
were used for all studies as negative controls. The tissue slides were visualized using an Olympus 
IX83 confocal microscope and Hamamatsu digital camera. 
 The slides were examined via confocal microscopy in a total of 10 fields of colonic mucosa 
starting with a random sample area by the use of DAPI channel; images were subsequently 
acquired. The positive fluorescent cells expressing CD11b, FOXP3, CD3, F4/80, CD4+ T cells, 
Ki-67, CD103, CD31 or Lgr5 were enumerated per mm2 of tissue. For calculation of the 
microvessel density, the percentage of the CD31 area was divided by the total pixels of the mucosal 
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area of each image tile, using ImageJ software45  (Figure 3.2). In this study, MSCs were labeled 
with fluorescent DiD® or DiR® dye (Invitrogen, Eugene, OR) for tracking, and mice were imaged 
using an IVIS instrument (PerkinElmer®, Waltham, MA). 
 
3.3.7 Microbiome 16S rRNA sequencing 
DNA of the fecal bacteria from all mice was extracted using a Mobio PowerSoil DNA 
Isolation kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Extracted DNA 
was submitted to Novogene Corporation (Chula Vista, CA) for 16S rRNA sequencing. Data 
analysis was also performed by Novogene. 
 
3.3.8 Statistical analysis 
 In this study, data were analyzed using Prism 7 (GraphPad, San Diego, CA), and the results 
are shown as the mean ± SD (unless otherwise stated), with the significance set at p < .05. The 
normality of the data was examined using the Shapiro-Wilk normality test. Significant differences 
among the groups were evaluated using one-way ANOVA with multiple comparisons using 




3.4.1 iMSC and adMSC phenotypic characterization 
 An evaluation for iMSCs and adMSCs was performed following the mesenchymal stem 
cell characteristics and identification criteria, as established by the International Society for 
Cellular Therapy 46. The flow cytometry analysis indicated that MSC highly expressed the 
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following markers: CD29, Sca-1, CD44, CD106, and CD73. No leukocyte marker expression was 
identified, including CD31, CD45, and CD11b (Figure 3.3A). It was noted that while adMSCs had 
high expression of CD90, the iMSCs were negative for CD90. In addition, the two cell types were 
positive for CD106 expression, which was demonstrated solely on MSC and not on skin 
fibroblasts. Tri-lineage differentiation also indicated that both cell types were capable of 
differentiating into adipocytes, chondrocytes, and osteoblasts (Figure 3.3B). 
 
3.4.2 Effects of MSC administration on clinical signs and colonic lesions in mice with DSS-induced 
colitis  
It was noted that the mice treated with DSS in the drinking water for approximately 7-10 
days showed clinical signs that corresponded with progressive colitis, including sustained bloody 
diarrhea, weight loss, and abnormal fecal consistency, which resulted in reduced clinical scores 
over time (Figure 3.4). After the signs of colitis developed in all mice, MSCs were administered 
on days 10, 13 and 16 at a dosage of 1x106 MSCs per mouse per intravenous injection. The mice 
that were treated with adMSCs or iMSCs were noted to have significantly reduced clinical scores 
compared to the mice that were treated with DSS without stem cells (adMSC treated mice, p = 
0.001 and iMSC-treated mice, p = 0.003) (Figure 3.4A). Within the first day of the first MSC 
injection, an improvement in the clinical scores was noted and was maintained during the MSC 
injection period, while the clinical scores continued to become worse in the animals that were in 
the DSS group without stem cell treatment. 
An evaluation of the gross lesion scores and histopathology of the distal colon was 
performed from the tissues collected in the mice euthanized at 72 hours after the third injection of 
stem cells (day 19 of DSS treatment). For the mice that were treated with only DSS, the colon was 
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noted to have shortened and was hyperemic (data not shown). Histologically, colonic tissues from 
the DSS-treated mice exhibited severe infiltration of inflammatory cells, necrosis, extensive 
mucosal erosion to ulceration, variable degrees of colonic gland ectasia and occasional complete 
loss and collapse of the mucosal architecture (Figure 3.4B), consistent with reports from previous 
studies42, 44, 47. In contrast to no stem cell treatment, the colonic tissues from the mice treated with 
iMSCs or adMSCs showed an overall improvement in the transmural inflammation, with 
significantly reduced infiltration of inflammatory cells in the lamina propria, decreased mucosal 
collapse and diminished mucosal ulceration and granulation tissue formation. The overall 
inflammatory scores assessed by H&E histopathology were considerably improved in the mice 
treated with adMSCs or iMSCs (adMSC, p = 0.003 and iMSC, p = 0.002; Figure 3.4C) compared 
to the DSS only treated group. Thus, these outcomes showed that iMSCs were equivalent to 
adMSCs in their potency to ameliorate the intestinal inflammation signs induced by DSS treatment 
in this mouse model of IBD. 
 
3.4.3 Trafficking of MSCs to intestinal and extraintestinal tissues  
To demonstrate the homing of MSCs to places of colonic inflammation, MSCs were 
labeled using DiR® dye immediately before injection. Cell migration was monitored using IVIS 
live animal imaging. These investigations showed that labeled MSCs were primarily distributed to 
the lungs at the beginning and were subsequently found in the liver and spleen (Figure 3.5A). 
However, labeled MSCs could not be detected by IVIS imaging of intestinal tissues, which 
suggests that few cells migrated to the sites. 
   To increase the sensitivity of cell detection, mice were injected with DiD®-labeled MSCs 
(Figure 3.5B) and were then processed for immunohistochemical examination of the tissues from 
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injected mice (Figure 3.5C-G). These studies showed that labeled MSCs could rarely be identified 
in the colonic mucosa and submucosa (Figure 3.5D, E), Peyer’s patches (Figure 3.5F, G) and 
mesenteric lymph nodes (Figure 3.5C) of the treated mice. Labeled MSCs were abundant in the 
spleen (Figure 3.5C) and lung tissues (data not shown). The relative paucity of MSC in colonic 
tissues following intravenous injection in the DSS model is correlated with some previous 
studies13, 22, 48, 49; however, it differs from reports in other published work in which high numbers 
of labeled MSCs were identified in intestinal tissues23, 50, 51. The very low numbers of MSCs in 
colonic tissues found in our study imply that the therapeutic benefits of injected MSCs were more 
likely to have been involved by paracrine secreted factors than by direct cell-to-cell effects between 
MSCs and colonic epithelial cells. 
 
3.4.4 Effects of MSCs administration on epithelial regeneration 
The histologic findings of colonic tissues from MSC-treated mice exhibited a noticeable 
recovery of the intestinal mucosal integrity (Figure 3.4B). These findings showed that the MSC 
treatment might have a direct effect on colonic epithelial regeneration. The stimulatory effect on 
epithelial regeneration could be mediated by several trophic factors, including promoted 
neovascularization, increased intestinal stem cell numbers, and enhanced epithelial proliferation 
and differentiation52, 53. In this study, we examined the immunohistochemistry of colonic tissue 
stained by markers regarding these factors indicating epithelial regeneration in mice treated with 
iMSCs and adMSCs compared to DSS without stem cell treatment (Figure 3.6). 
We observed a significant increase in the numbers of Ki-67+ colonic epithelial cells of the 
iMSC and adMSC treated mice, compared to the numbers of Ki-67+ epithelial cells in the DSS-
only treated and untreated control mice (Figure 3.6A, B). Moreover, the number of Lgr5+ intestinal 
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stem cells had significantly increased in the colonic mucosa of the animals treated with MSCs, 
compared to the DSS-only treated or control animals (Figure 3.6C, D). Finally, the mice injected 
with MSCs showed a significant increase in angiogenesis as determined by the higher numbers of 
CD31+ endothelial cells, with a high mean vessel density and area compared to the control animals 
(Figure 3.6E, F).    
Overall, the results indicate that systemic administration of iMSCs or adMSCs provides a 
vital trophic effect on intestinal epithelial cells by promoting proliferation and recruiting intestinal 
stem cells, as well as supporting intestinal blood supply by increased local angiogenesis. Thus, 
these results suggest the secretion of various trophic mediators by intravenously delivered MSCs. 
The stem cell tracking data and the limited number of MSCs identified in colonic tissues imply 
that the trophic factors were likely to have been produced at the remote area far away from the GI 
tract.  
 
3.4.5 Administration of MSCs reverses microbiome dysbiosis  
Alteration of the intestinal microbiome in a mouse model of DSS-induced colitis was 
observed in a previous study54. In our study, we determine the composition of the gut microbiome 
of DSS-treated mice using 16S rRNA sequencing and microbiome analysis. We also found 
considerable alterations in the bacterial populations of other important phyla (Figure 3.7). For 
example, we observed a dramatic increase in Proteobacteria (Figure 3.7A), increased Bacteroides, 
and decreased Firmicutes in the mice that were treated with DSS, compared to the untreated control 
animals (Figure 3.7D). In general, the DSS without stem cell treatment had the least microbial 
community diversity measured within a sample as indicated in an alpha diversity graph (using the 
Simpson index) (Figure 3.7B). The shared number of bacteria assigned in the groups was generated 
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according to the clustering of each treatment shown in the Venn diagram (Figure 3.7E). We 
determined the DSS-only group had the least bacterial sharing with the healthy mice.   
Furthermore, the number of bacteria shared between the groups which were generated 
according to the clustering of each treatment group. We determined that the DSS-only group had 
the least bacterial group sharing with the healthy mice. 
It is important to note that in the mice treated with iMSCs or adMSCs, after 10 days of 
stem cell treatment with ongoing DSS supplement, the composition of the microbiome in these 
animals recovered to a population that almost remarkably resembled that of the microbiome of 
healthy untreated mice (Figure 3.7C). For example, the group of animals treated with iMSCs had 
a corresponding taxa distribution relative to the healthy control animals, compared to the DSS only 
animals or the DSS animals treated with adMSC (Figure 3.7D). These findings indicate that 
treatment with MSCs provides the optimal microenvironment for colonic flora recovery to normal, 
although the specific mechanism of the effect remains unknown.    
 
3.4.6 Effects of MSC administration on intestinal inflammation. 
 We examined the effect of MSC injection on inflammatory responses in the colon and 
regional lymphoid tissues. In the colonic tissues of the DSS-treated animals, increased infiltrates 
of F4/80+ and CD11b+ macrophages, CD3+, CD4+ T cells, and CD103+ inflammatory monocytes 
were identified, compared to the colonic tissues of the healthy untreated animals. 
In the mice that received an MSC injection, significantly lower numbers of macrophage 
and monocyte infiltration in the tissue were observed compared to DSS without MSCs (Figure 
3.8A). FOXP3+ regulatory T cells were significantly greater in the colonic tissues of the mice 
treated with iMSCs or adMSCs, compared to the control animals or DSS-only animals (Figure 
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3.8A). These findings agree with the findings of previous studies13, 22. This suggests that MSC 
treatment inhibits colonic inflammation, as shown by increased regulatory T cells and decreased 
macrophage and neutrophil infiltration into the lamina propria. However, MSC treatment in our 
study did not change the numbers of infiltrating T cells in colonic tissues (Figure 3.8A).   
Importantly, iMSCs and adMSCs could be compared in their effects on lowering the 
severity of colonic inflammation. However, there were no changes in the T cell, B cell or myeloid 
cell populations in the lymphoid tissue (spleen or mesenteric lymph node tissues) of the animals 
treated with MSCs, compared to untreated colitis (Figure 3.8B). Thus, the administration of MSCs 
decreased local colonic inflammation, together with stimulating angiogenesis and epithelial cell 




The use of conventional allogenic BMMSCs or adMSCs to treat IBD has resulted in a 
promising outcome in preclinical studies in laboratory animal models. It is also advantageous in 
experimental clinical trials in humans13, 14, 17, 23, 32, 50, 55, 56. Although positive outcomes using MSCs 
have been continuously reported, several important drawbacks appear to be the limitations for 
conventional stem cells, including the limited proliferative capacity of aging MSCs, donor 
variability, costs and time expense for the selection and expansion of the cells in primary culture33, 
36, 57. Thus, other inexhaustible cell sources with the constant function of MSCs are required for 
cellular therapy. In previous studies, the potential advantages of iPSC-derived MSCs (iMSCs) for 
cellular therapy have been described37, 38, 41, 58. However, a lack of studies focus on the use of 
111 
 
iMSCs in IBD models. Therefore, in this study, we have investigated the potential use of iMSCs 
as an additional cell source for the treatment of IBD. 
We found that iMSC were equal to or in some cases better than conventional adMSCs for 
the treatment of IBD in terms of improving the clinical signs of colitis and stimulating intestinal 
healing. For example, the general clinical score in iMSC-treated mice was decreased by 26% at 
day 19, compared to DSS-only mice (Figure 3.4A), while the reduction of the score was 19% in 
mice treated with adMSCs. Moreover, the intestinal inflammation was equivalently decreased in 
mice that received an iMSC injection compared to adMSC-treated mice (Figure 3.4C). 
Furthermore, iMSC administration showed a remarkable stimulation of intestinal epithelial cell 
proliferation, increased numbers of Lgr5+ intestinal stem cells, and augmented intestinal 
angiogenic responses (Figure 3.6). 
Previous studies have described the anti-inflammatory properties of MSCs that potentially 
effect and may be responsible for a part of the overall beneficial effect of MSCs on colitis in this 
study. However, our study suggests alternative processes by which MSCs may result in an equal 
or greater effect on ameliorating lesions in the gut associated with IBD. For example, stimulation 
of epithelial regeneration may be necessary for healing when the inflammation is suppressed. The 
significantly greater number of Lgr5+ stem cells in the intestinal mucosa found in mice treated 
with adMSC or iMSC, compared to control DSS mice (Figure 3.6C, D), indicates the regenerative 
activation of the microenvironment via local stem cell recruitment and/or proliferation. In addition, 
our result shows the remarkable proliferation of mature epithelial cells in the colonic mucosa 
corresponding to the stimulatory properties of secretory factors derived from MSCs. 
Considering the limited MSC distribution to the colonic mucosa and submucosa (Figure 
3.5D, E), the MSC effect may be predominately influenced by secretory trophic factors from 
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resident MSCs at extraintestinal tissues, including the spleen and the lung. Finally, we also found 
that angiogenic responses were significantly enhanced locally in colonic tissues in mice treated 
with MSCs, which is consistent with the release of pro-angiogenic cytokines, such as VEGF, as 
previously reported59. 
Microbiome alterations are considered a second potential mechanism by which MSCs can 
stimulate intestinal healing. The gut microbiome plays an important role to locally produce a 
stimulatory effect on immune responses and intestinal integrity60. For example, abnormal healing 
of the intestine has been shown in mice in which the microbiome has been disrupted, as well as in 
mice unable to detect the intestinal bacteria due to interrupted TLR signaling61, 62. 
In the present study, we observed that the altered microbiome caused by DSS induction 
was, to a large degree, reversed by the MSC treatment, including the administration of iMSCs or 
adMSCs (Figure 3.7). For example, the diversity of the gut microbiome taxa was significantly 
increased in MSC-treated mice, compared to DSS only treated mice (Figure 3.7B). Therefore, 
these findings suggest that by generating a more diverse microbiome that resembles healthy control 
animals, thereby leading to an increased production of trophic substances for the support 
microenvironment, MSC administration improved the overall intestinal health and healing. 
However, it is not clear whether the changes of the microbiome were due to an improvement in 
intestinal healing or microbiome restoration causing the intestinal healing. It is also possible that 
the two mechanisms were likely to be operating with MSC-induced changes in the colonic 
epithelium causing alterations in the microbiome and subsequently affecting intestinal 






In summary, our studies show that iMSCs are equally as effective as adMSCs when 
systemically administered to ameliorate IBD in a mouse model, and they do not induce detectable 
adverse effects, even when intravenous administration is repeated. Moreover, the effects of MSCs 
on IBD are likely to be multifactorial regarding the gut homeostasis restoration, including 
improved intestinal epithelial regeneration, beneficial microbiome alterations, and suppression of 
intestinal inflammation. For future application, we have also initiated a study to evaluate the safety 
and efficacy of iMSC treatment in a clinical trial of a spontaneous IBD model in pet dogs based 
on the early evidence of MSC efficacy in a similar model16, 63. Moreover, we have recently 
conducted safety studies for systemically administered canine iMSCs in dogs and found no 
evidence of teratoma or tumor formation. Thus, the use of systemically administered iMSCs as a 
new cellular therapy is an option for the management of refractory IBD, provided regulatory and 





Figure 3.1 Gating strategies for flow cytometry. Gating was done by initially selecting 
lymphocyte and myeloid cell populations by FS-A and SS-A parameters, then gating for singlets.  
Next, CD45+ cells were selected for further analysis, which initially included gating for CD4+ and 
CD8+ events. B cells were selected based on B220 staining, while regulatory T cells were 
identified from the CD4+ population by intracellular staining for FOXP3.  Abbreviations:  SS-A, 
side scatter area; MLN, mesenteric lymph node; FOXP3, foxhead box P3; Treg, regulatory T cell, 
Th, T helper cell. 
 
 
Figure 3.2 Immunofluorescence image analysis by ImageJ software.  Quantitative image 
analysis was done using ImageJ software. A mask layer corresponding to the interested population 
was created, and the analysis was performed with settings consistently applied through all group 
comparisons. For example, displayed images represented the area of CD31+ cells which were 






Figure 3.3 Phenotypic characterization of iMSC and adMSC. (A): Expression of cell surface 
determinants using flowcytometry.  Specific antibody staining depicted in red, whereas isotype 
control staining for each displayed in blue. The percentage of the positive staining for each marker 
was indicated.  (B): Tri-lineage differentiation of passage 3 MSC, as described in Methods.  
Adipocytes detected using Oil Red O (200X); chondrogenesis by Alcian Blue, and osteogenesis 
by Alizarin Red staining at day 12 after differentiation. Abbreviations:  adMSC, adipose-derived 




Figure 3.4 Effects of MSC administration on clinical scores and inflammatory score in DSS-
induced colitis mice. Mice were monitored for percentage of weight loss, fecal occult blood, and 
fecal consistency every day during DSS treatment period (19 days) and a total clinical score was 
calculated. (A): Clinical score over time in 4 groups of mice (n = 5 per group): control, DSS treated 
+ PBS; DSS + iMSC, and DSS + adMSC.  MSCs were administered by tail vein on days 10, 13 
and 16. (B): Histology of colonic tissue sections from one mouse from each of 4 treatment groups, 
based on H&E stained sections. (C): Quantitative inflammatory scores assessed by H&E 
histopathology, as described in Methods.  Data was transformed to a normal distribution and the 
statistical differences were calculated using (A) repeated measures One-way ANOVA with 
Tukey’s adjustment, (B) One-way ANOVA with Tukey’s adjustment (*p ≤ .05, **p ≤ .01, ***p ≤ 






Figure 3.5 Localization of labeled MSC in live animals and tissue sections.  (A): For in vivo 
localization, MSCs were labeled using DiR® dye before injection and mice were monitored by 
IVIS in-vivo fluorescent imaging at 24 hours after the first injection, 72 hours post-injections and 
on the day of euthanasia. High concentrations of MSC were found in lung and liver and spleen, 
but not in intestinal tissues.  (B):  In vitro labeled MSC using fluorescent labeled (DiD®).  
Localization of labeled MSCs in colonic mucosa and regional lymphoid tissues, tissues were 
collected 10 days after MSC administration.  (C): Presence of labeled MSCs in spleen and 
mesenteric lymph node tissues. (D): Labeled MSC in colonic mucosa (arrow) presented in 
corresponding channel (E): High power views of labeled MSC in colonic mucosa and submucosa. 
(F and G): Labeled MSC in Peyer’s patch of colon (arrow).  Scale bar indicated 50 µm in all panels 
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Figure 3.6 Effects of MSC administration on intestinal epithelial cell proliferation, stem cell 
recruitment, and angiogenesis. (A): Immunoflourescence detection of Ki-67+ (red) cytokeratin+ 
(green) intestinal epithelial cells in colonic tissues from mice with DSS-induced colitis, with or 
without MSC treatment.  (B): Graphical representation of numbers of Ki-67+ epithelial cells/ 5 
villi. (C): Immunofluorescence detection of Lgr5+ intestinal stem cells (red) at the base of colon 
crypts in colonic tissues from control and MSC-treated mice.  (D): Graphical representation of 
numbers of Lgr5+ stem cells/mm2 tissue.  (E): Immunofluorescence detection of CD31+ 
neoangiogenic cells in colonic tissues of control and MSC treated mice. (F): Graphical 
representation of the mean vessel density and mean vessel area / mm2 of mucosa, as determined 
as described in Methods. The statistics reported as mean ± SD, statistical differences were 
calculated using One-way ANOVA with Tukey’s adjustment (*p ≤ .05, **p ≤ .01, ***p ≤ .001, 
****p ≤ .0001). Scale bar indicated 50 µm in all panels.  Abbreviations:  CKs, cytokeratin; DAPI, 
4',6-diamidino-2-phenylindole; Lgr5, leucine rich repeat containing G protein-coupled receptor 5; 






Figure 3.7 Effects of MSC administration on gut microbiome.  Fecal pellets were collected at 
2 days after the last MSC injection from control and MSC-treated animals (n = 5 per group) and 
analyzed by 16s rRNA sequencing as determined as described in Methods.  (A): Relative 
abundance of Proteobacteria presented in each treatment group. (B): Microbial diversity within 
treatment groups (Simpson alpha diversity index) calculated with QIIME (Version 1.7.0). (C): 
Comparative analysis of differences between treatment groups (beta diversity), heat map 
represents average differences, with 0 as no difference, 0.3 is maximum differences. Scale bar 
shown in bottom left. (D): Relative abundance of top 10 phyla presented in each treatment group. 
(E): Venn diagram generated according to the Operational Taxonomic Unit clustering of each 
treatment group, each number represents number of bacterial species, either shared or unique to 
treatment groups. The statistics reported as mean ± SD, statistical differences were calculated using 





Figure 3.8 Effects of MSC administration on colonic inflammation. Tissue sections were 
immunostained with the indicated antibodies, as noted in Methods, and imaged using a confocal 
microscope.  Quantitative image analysis was used to quantitate the density of inflammatory cells 
(see Methods). (A): Distribution of FOXP3, F4/80, CD11b, CD3, CD4 T cell and CD103+ cells 
in colonic tissues.  (B):  Leukocyte populations in spleen and mesenteric lymph node tissues as 
assessed by flow cytometry (see Methods). Statistical differences were calculated using One-way 
ANOVA with Dunnett multiple comparison to DSS treated group (*p ≤ .05, **p ≤ .01, ***p ≤ 
.001, ****p ≤ .0001). Abbreviations: FOXP3, Foxhead Box P3; DAPI, 4',6-diamidino-2-
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CHAPTER 4: RESPONSE OF CANINE MSC TO INFLAMMATORY CYTOKINES AND 
TOLL-LIKE RECEPTOR (TLR) AGONISTS AND THEIR INTERACTION WITH IMMUNE 





Background: Inconsistent therapeutic effect using the conventional MSCs have been reported, 
and MSCs activation by inflammatory cytokines and TLR agonists has been reported in species 
other than the dog to improve the efficacy of MSCs treatment. However, the overall alteration of 
features and functions of canine MSCs by preconditioning with those stimuli is mostly unknown. 
Therefore, the studies described here investigating the effect of preactivated MSCs and their 
interactions with other cells.    
Objective: This study comprehensively investigated the response of canine MSCs to inflammatory 
stimuli and their interactions with immune cells and cells from the joint microenvironment. We 
hypothesized that IFN-g and Poly(I:C) would more potently activate dog MSC than the other 
stimuli.  
Result: Stimulation of dog MSC with inflammatory stimuli elicited little response in terms of 
either cell surface phenotype changes or immune functional changes, indicative of a hypo-
responsive state.  The only detectable changes were an increase in PD-L1 expression following 
IFN-g exposure, and increased secretion of IL-8 following Poly(I:C) exposure.  Pre-activation also 
had no effect on the interaction of MSC with macrophages or with fibroblasts.  
Conclusion: Dog MSC appeared to be hypo-responsive to activation with key inflammatory 
cytokines or TLR agonists, relative to other species.  The reasons for this lack of responsiveness 
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are not known but could reflect differences in receptor signaling strength or expression, in 




 MSCs have advantageous properties including multi-lineage potential, self-renewal, rich 
tissue source with easy accessibility, isolatable and expandable in vitro with exceptional genomic 
stability and few ethical issues1. MSCs are conveniently accessed from several sources from adult 
tissue including bone marrow2 , adipose tissue 2, dermis3, 4 and more. MSCs are also considered 
the immune-privilege cells since the lack of co-stimulatory molecule expression5 prevents them 
from immune recognition and support the use of allogenic MSC source 4. MSCs are also well-
known in their anti-inflammation effect to immune cells (as described previously).  These support 
the MSCs as a promising alternative cellular therapy in various immune disorders including SLE, 
graft-versus-host-disease (GVHD), osteoarthritis (OA) and IBD 1, 6, 7.  
The conventional MSCs have been documented for their advantageous features, and 
effective for treatment in inflammatory diseases1, 6, 7. However, inconsistent efficacy using the 
conventional MSCs in several studies have been reported ranging from less effective to ineffective 
outcomes8. For example, studies in human MSC treatment found no effect of conventional MSC 
unless preactivation the MSCs by inflammatory stimuli 9, 10 prior treatment. Additionally, the final 
immunomodulatory outcome of MSC is influenced by the microenvironment cues at the site of 
inflammation 11. Several studies indicated that MSCs are attracted to the sites and become 
activation by inflammatory stimuli including  IFN-g 12-15, TNF-a 15, and LPS 14, 16. Previous studies 
in human and mouse documented an increase of MSC efficacy by those stimulations, despite the 
short period of incubation time (i.e., 1 hour17), which are postulated to resemble the endogenous 
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response occurring to MSCs at the site of inflammation17 in vivo. These pieces of evidence suggest 
the plausible way to improve the efficacy of MSC treatment by preactivation the stem cells by 
inflammatory cytokines and TLR agonists in vitro prior administration for treatment.  
Precondition MSCs with inflammatory cytokines and TLR agonists showed higher 
effective function of MSCs both in immunomodulatory and tissue regeneration effect15, 18-21. 
Several studies have been reported the increase of anti-inflammation and augmentation of tissue 
regeneration through the secretory factors produced by preactivated MSCs, as well as cell-cell 
contact activity13, 15, 18-23. Preactivated MSCs with TNF-a, IFN-g, LPS, Poly(I:C) or IL-1B have 
been noted to produce a significant amount of cytokines, growth factors, chemokines and adhesion 
molecules including IL-10 24, HGF 13, TGF-b 25, PGE-215, IDO25, 26, VEGF 13, 27, CCL228, and 
VCAM-124. Some of these mediators were reported to enhance the migratory ability of MSC to 
the affected area22, 24 as well as ability to support the growth of cells including fibroblasts28, 29, 
epithelium and synoviocytes.  Moreover, they become more suppressive phenotype inhibiting the 
immune cell activity including suppressed T cell proliferation and macrophage polarization (as 
described in a previous section) which are crucial for treating inflammatory diseases. 
Although previous studies found that preactivation of MSCs showed an increased efficacy, 
the actual effects derived from each stimulus remain controversial and potential a bidirectional 
activity11, 24, 26, 28, either immunosuppressive or pro-inflammation. For example, an increase of IL-
8 was found in Poly(I:C) activated MSCs in one study20 but not in another study25, even the same 
stimulation dosage and incubation period. Also, no agreement exists in other studies regarding the 
optimal protocol to yield the best stimulation effect. Various combination of time and dosage have 
been reported to be useful for MSCs activation 15, 16, 18-21, 30, 31. For example, the effective doses 
from 2ng 30-100ng/ml29 and various incubation times (i.e., 1 hour 20, 25, 24 hour31 to 5 days16) have 
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been reported for IFN-g activation. Thus, the optimal activation for proper MSCs function remains 
a challenge and crucial for determining the ideal outcomes.  
At present, most of the results regarding preactivation MSCs have been reported from 
mouse and human. In particular, TLR-mediated responses are considered both species-specific and 
cell-type specific32. Very limited studies have investigated the effect of MSCs activation in dog 
and some significant differences between interspecies have been considered. For example, 
previous studies in murine and human found that IL-10 was not constitutively produced by resting 
MSCs however, only human MSCs was shown an increase of IL-10 production in response to 
Poly(I:C) activation 15. Unfortunately, the knowledge on overall alteration of features and function 
of MSCs by preconditioning with those stimuli has been mostly unknown in dog MSCs. Therefore, 
the extensive studies regarding preconditioning MSCs in dog is required.  
This study investigates the response of canine MSCs to inflammatory cytokines and TLR 
agonists and their interactions with immune cells and cells from the joint microenvironment. The 
results of stimulation with following stimuli; IFN-g, TNF-a, Poly(I:C) and LPS; that effect to the 
immune cells and cells from joint microenvironment are investigated and compared to 
unstimulated MSCs. Preactivation MSCs with inflammatory cytokines and TLRs agonists 
generally showed the equivalent effects to the resting MSCs in the most parts except increased 
PD-L1 expression by IFN-g and unique high IL-8 secreted by Poly(I:C) activation. Alternative 
macrophage phenotype was induced by most of the stimuli as well as unstimulated MSCs. 
Significant regenerative responses of fibroblast and synoviocytes were stimulated by MSC-CMs 
with the comparable effect between intact and unstimulated cells. Compared to other species, 
canine MSCs showed the hyporesponsive response to inflammatory stimuli suggesting the 
interspecies variable of cytokines and TLR-mediated response. 
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4.3 Materials and Methods 
 
4.3.1 MSCs isolation, culture and stimulation procedures 
 The MSCs used in this study were derived from frozen-stored fat tissue of healthy dog 
donors. Briefly, 0.5 gram of fat tissue was thawed and washed with sterile PBS, then mechanical 
minced by scalpel and digested by collagenase for 30 minutes at 37°C. The stromal vascular 
fraction was isolated by centrifugation at 380xg for 5 minutes. After twice washes with complete 
medium (DMEM with 10% FBS, 1% Penicillin-streptomycin, essential and non-essential amino 
acid), SVF was transferred to 75 cm2 tissue culture flask. The cells were incubated at 37°C, 5% 
CO2 and allowed 72 hours for cell adhesion to plastic. After 72 hours, the media was removed and 
refed with the fresh complete media. Proliferating cells were allowed to grow and reach 70% 
confluency with media change every 48 hours. The adherent cells were passaged according to 
confluent. Trypsin was used to detach the cells from flasks, and the cells were washed and 
transferred to 225 cm2 tissue culture flask. In this study, 6 MSC lines were derived from adipose 
tissue from 6 dogs, and 4-6 MSCs were used in each experiment implied that 4-6 biological 
replicates were done. All MSCs used in this study were within passage 3-6.  
 Total of 5 MSC-conditioned media (MSC-CMs) derived from different treatments as 
following;1) IFN-g-MSC-CM, 2) TNF-a-MSC-CM, 3) Poly(I:C)-MSC-CM, 4) LPS-MSC-CM, 5) 
Ctrl-MSC-CM were examined. Briefly, MSCs were detached and obtained the cell suspension, 
washed and pelleted by centrifugation. The MSCs were stimulated by one of following reagents; 
recombinant canine IFN-g (10ng/ml; R&D Minneapolis, MN), TNF-a (10ng/ml; R&D), Poly(I:C) 
(10ug/ml; Sigma-Aldrich, St. Louis, MO), LPS (1 ug/ml; Sigma-Aldrich). Those prepared reagents 
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were added to the fresh complete media, then resuspended the cells with conditioned media to get 
the optimal concentration at 1 million cells/ml. MSCs were incubated for 1 hour at 37°C, 5% CO2 
with often shaking every 10 minutes. After 1 hour of stimulation, MSCs were washed twice, refed 
with the new fresh condition medium at a concentration of 1 million cells/ml, and plated in 24-
well plate with 0.5 ml/well. The unstimulated cells were processed the same incubation method 
with the control complete media. The plates were incubated further 24 hours and the supernatants 
from each treatment were collected and centrifuged to separate the dead cells and debris at 400xg 
5 minutes, then transferred to new eppendorf and stored at -80°C until used. Most of the 
downstream assays were used supernatant derived from MSCs (MSC-CMs); otherwise, the 
stimulated (or preactivated) cells were used instead of MSC-CMs for assay of T cell suppression 
test as indicated in the text.   
 
4.3.2 Phenotype assessment by flow cytometry. 
 The phenotypic evaluation of preactivated MSC and control MSC were performed as 
described previously33. Briefly, after MSC-CM was collected, the MSCs were detached and 
processed for the single cell suspensions (1x106 cells/ml) in FACS buffer and 1 X 105 cells were 
immunostained in single wells of round bottom 96-well plates. The following antibodies (all from 
San Diego, CA) were used for immunostaining; MHCII-FITC (YKIX334.2), CD73-PE (clone 
TY/11.8), CD90-APC (clone YKIX337.217), purified PD-L1 (clone 4F2). The cells with primary 
antibody were incubated for 30 minutes at room temperature and shielded the light. After complete 
incubation, the cells were washed twice with FACS. For PD-L1 staining, the donkey anti-mouse 
Cy3 conjugated antibody was used as the secondary antibody. For phenotypic evaluation of 
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activated macrophage, macrophages obtained after MSC-CMs incubation were detached and 
processed immune staining with MHCII (same staining method as described previously).  
Phenotype evaluation of synoviocytes were processed with the same protocol. Briefly, 
synoviocytes were plated in 48-well plates followed by MSC-CM incubation for 24 hours. Then, 
the cells were harvested and immunostained. Anti PD-L1 and MHC II used in the tests also the 
same clone. Cells were examined using Beckman Coulter Gallios flow cytometer (Brea, CA) and 
data were analyzed using FlowJo Software (Ashland, OR).    
    
4.3.3 ELISA for measured the cytokines produced by preactivated MSC 
 The concentration of cytokines produced from preactivated MSCs were measured by 
sandwiched ELISA (DUOSET; R&D) followed manufacturer guidelines. The cytokines included 
IL-6, IL-8, VEGF, IL-1B, MCP-1, IL-10 and TNF-a. Also, the supernatant derived from 
macrophage activation assay was measured for TNF-a and IL-10 production. The ELISA has 
performed in total at least 3 independent MSC donor with triplicates. The readouts parameters 
were reported both protein concentration (pg/ml) and the ratio from unstimulated cells. 
 
4.3.4 T cell proliferation suppression test with EDU 
 Blood from healthy dogs was processed to obtaining peripheral blood mononuclear cells 
(PBMCs). Briefly, EDTA-anticoagulated blood was processed the separation of PBMC by Ficoll-
density gradient isolation according to the manufacture’s protocol.  The PBMCs were washed and 
resuspended with complete medium (RPMI with 15% FBS, 1% Penicillin-streptomycin, essential 
and non-essential amino acid) at the concentration 1 million cells /ml. 
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 This assay used the activated MSCs (not MSC-CMs) and co-incubated with the PBMCs 
since the preliminary study showed that the MSC-CMs of dog could not suppress T cell 
proliferation. MSCs were stimulated by the stimuli as described previously. Moreover, the 
preactivated cells were detached and washed twice with PBS and resuspended with the complete 
media. The MSCs were counted, and 20,000 cells were plated to each well of 96-well plate and 
allow the cells adhered to the plastic for 2 hours. Then aspirate the media out and put the 200 ul of 
PBMC suspension (prepared as previously described) into each well so the proportion of MSCs vs 
PBMCs was 1:10. The T cell proliferation with the addition of preactivated MSCs was analyzed 
using EDU (5-ethynyl-2′-deoxyuridine).  Briefly, the experimental wells (direct culture of PBMCs 
and MSCs) were activated using Concavalin A at 10ug/ml. After 48 hours of reaction, 10uM EDU 
(Life Technologies Corp. Grand Island, NY) was added to the co-culture. Next 24 hours, the non-
adherent cells were collected and immune stained for the detection of canine CD5+ cells (clone 
YKIX322.3, ABD Serotech. Raleigh, NC). Then, the cells were fixed with 4% PFA for 10 minutes 
and permeabilized with saponin-based permeabilization reagent (Life Technologies Corp. Grand 
Island, NY). The reagent of staining cocktails containing 1mM Copper (II) sulfate pentahydrate 
(CuSO4 ·5H2O), 50mM L-Ascorbic acid (Sigma-Aldrich, St. Louis MO). 1 uM Sulfo-Cyanine3 
(Cy3) azide (Lumiprobe Corporation, Hallandale Beach, FL) was added to each well and incubated 
for 30 minutes at room temperature. After complete staining, cells were washed and evaluated 
using the flow cytometry. Percentage of T cell proliferation and mean fluorescent intensity (MFI) 
of EDU were analyzed using Flowjo software. 
 
4.3.5 Macrophage activation with LPS 
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 To investigate the effect of MSC-CMs on macrophage activation, the monocyte-derived 
macrophages were set up. Briefly, PBMC from a healthy donor was processed as described 
previously. Then, PBMCs were resuspended with complete medium and plated at a density 1x106 
PBMC/0.5 ml in 48-well polystyrene cell culture plates, incubated for 4 hours at 37°C.  After 
allowing for adhesion, the non-adherent cells were washed twice and refed with complete medium 
with 15% FBS, supplemented with 10 ng/ml huM-CSF (Peprotech, Rocky Hill, NJ, USA). The 
medium was changed every 2 days, and after 7 days in culture, the macrophages were stimulated 
with LPS (100ng/ml) for 2 hours then adding fresh medium alone (control) or medium plus 50% 
of MSC-CMs for 2 hours. After complete incubation, the culture macrophages were washed twice 
with PBS and refed with 500 ul of fresh media and culture for an additional 24 hours. The next 
day, macrophage supernatant was collected, and macrophages cells were detached and prepared 
for phenotype assessment (described previously). 
 
  4.3.6 Macrophage polarization evaluated by immunocytochemistry (ICC) 
 Monocyte-derived macrophages were cultured in 8-well chamber slides for 7 days. Then, 
the culture media was aspirated and refed with half of fresh media and half of MSC-CM from each 
condition per well. Also, the standard polarization of macrophages (M0, M1, M2) were used as 
the control. M0 stage was the cultured macrophage in fresh medium. M1 were obtained by adding 
20ng/ml of canine recombinant IFN-g in the media. M2 were derived from macrophage incubated 
with a mixture of recombinant canine IL-4 and IL-13 (20ng/ml each; R&D). All treated wells were 
incubated for a total 24 hours and then fixed with 2% PFA (Thermo Fisher, Waltham, MA). After 
washed twice PBS, the slices were prepared for immunofluorescence staining. Briefly, the 
permeabilization buffer using 0.1% Triton X was added and incubated for 15 minutes following 
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with blocking step for 1 hour and washed twice. The anti-iNOS (polyclonal, dilution 1:200) 
antibody and CD206 (clone 3.29B1.10, dilution 1:20) were incubated overnight with 0.25% 
saponin at 4°C. The next day, the slices were washed twice followed by secondary antibody 
staining. Secondary antibodies (Alexa Flour®647 and Cy3; dilution 1:200 in PBST, Jackson 
ImmunoResearch Laboratories) were incubated for 30 minutes at room temperature. After twice 
wash, the slices were counterstained with DAPI (Molecular Probe, Eugene, OR), and subsequently 
mounted with Prolong® Diamond Antifade medium (Thermo Fisher, Waltham, MA). Appropriate 
isotype control were used for all studies as negative control. The macrophage slides were 
visualized using an Olympus IX83 confocal microscope. For image analysis of macrophage 
polarization, 10 random fields of 20x magnification were captured. The fluorescent intensity and 
number of positive cells corresponding to each marker were counted using ImageJ software. The 
results were reported both MFI for each marker and the ratio of CD206/iNOS (M2/M1 ratio).     
 
4.3.7 Scratch assay for Fibroblast migration  
 Canine fibroblasts were plated in 96 well-plate at 30,000 cells/well and cultured for 12-18 
hours to allow the cells adhesion to the bottom. Then, the monolayer of fibroblast was scratched 
using the WoundMakerTM. The wells were washed twice with media and refed with half of fresh 
media and half of MSC-CMs. For control well without CMs, half of fresh media and half of 
DMEM were fed in a total of 150 ul. The plated were cultured for 72 hours in the IncuCyteTM 
machine to assessing the migratory ability of fibroblast to cover the scratch area. The machine was 
programmed to assess the wound area by photo capture and serial image analysis every 3 hours. 
The parameters reported from the software including the wound width, % relative wound density, 
% relative wound confluence. Wound width is the area measured the gap width of scratch. % 
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relative wound density is the density of the cells inside the wound area relative to the area outside 
the wound. % wound confluence is the cell confluence within the wound region.  
 
  4.3.8 MTT assay  
 The cells (synoviocytes or fibroblasts) were plated into 96 well plates at the density of 
20,000 cells/well and incubated for 4 hours to allow the cells adhesion. The MSC-CMs were added 
with the fresh medium at ratio 1:1 and incubated for 48 hours. After 2 days, 10 ul of MTT (5mg/ml, 
Sigma, USA) was added to each well and the mixture was incubated for another 4 hours. Then, 
the solubilizing solution was added and vigorous mix. The optical density (OD) value of the 
samples was measured at 570 nm with a microplate reader.  
 
 4.3.9 Statistical Analysis 
  Data were analyzed using Prism 7 software (GraphPad, San Diego, CA, USA). The 
normality of the data was initially tested by Shapiro-Wilk normality test and parametric data were 
reported as mean ± standard deviation (SD). Data which were not normally distributed were shown 
in median (range). In parametric data, the statistical differences across all groups compared were 
analyzed using One-way ANOVA with Dunnett correction.  In some analysis, the results were 
calculated as the ratio from unstimulated MSC group and Kruskal-Wallis test with Dunn’s 
correction was used (as stated in the text). For the fibroblast migration over times, data was 
analyzed using 2-way ANOVA with Dunnett correction. Also, the results from repeated 
experiments including cytokine productions from different MSC donors were standardized to 






4.4.1 IFN-g induced a higher number of PD-L1+ve MSCs  
We examined the effect of preactivation on PD-L1, MHC II, CD73 and CD90 expression 
by flow cytometry analysis. The percentage of cells expressing each marker and their ratio to 
control MSCs have shown in Figure 4.1. We found that PD-L1, MHC II, CD73 were not 
constitutively expressed by resting MSCs and very small number of MSCs (roughly 0.5-1%) 
showed to have these markers on their surface. IFN-g stimulation increased the number of MSCs 
expressing PD-L1 for approximately 1.4 times (ratio; 1.044 - 1.8; p = 0.022) compared to resting 
MSCs (Figure 4.1A). We also found that resting MSCs started upregulating constitutive PD-L1 
after 24 hours in culture leading to the significant number of PD-L1+ve cells and the most drastic 
effect was found at 72 hours with the stimulus (Figure 4.2). CD90 was constitutively expressed on 
resting MSCs (69.83 ± 17.45%). There was no change in the ratio of CD90, MHC II and CD73 
expression in response to any pretreatment indicating no detectable effect from those preconditions 
on the expression of MHC II, CD73. In addition, we found that MHC II was intrinsically 
upregulated for 10% of the cells after 72 hours of culture (Figure 4.2) suggesting that MSCs 
became more immune recognizable in long term culture of MSCs. 
    
4.4.2 Enhance of cytokines production by Poly(I:C) 
    The cytokines production in response to inflammatory cytokines and TLRs activation 
was evaluated using ELISA. In our study, we found that resting MSCs constitutively produced IL-
1B, IL-6, IL-8, MCP-1, and VEGF (Figure 4.3). Specifically, the level of pro-inflammatory 
cytokines including IL-6 and IL-8 were approximately 100-200 pg/ml (IL-6; 170 ± 154.4, and IL-
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8; 72.84 ± 26.17), and level for IL-1B was less than 10 pg/ml. In contrast, resting MSCs 
intrinsically produced a large amount of VEGF (1,575 ± 861.8 pg/ml) and MCP-1 (10,100 ± 2,401 
pg/ml). Interestingly, Poly(I:C)-MSC secreted an extreme amount of IL-8 (1,538 ± 538.9 pg/ml) 
which was approximately 20-40 times greater than the amount produced in resting state (p 
<0.0001) as shown in Figure 4.3. However, the level of MCP-1, VEGF, IL-6, and IL-1B were 
unchanged after stimulation indicating no detectable effect from those preconditions on the 
production of those cytokines. Additionally, the level of IL-10 and TNF-a in MSC-CMs were very 
low and undetectable by the kits indicating that preactivation on canine MSCs did not affect the 
production of these cytokines.  
 
4.4.3 Impact of MSC activation on T cell and macrophage activity 
To investigate whether the activation of MSC alters their immune suppressive properties, 
the activity of immune cells in response to MSC activation were determined using T cell 
proliferation and macrophage activation assay. As shown in Figure 4.4A, the MSCs, either intact 
or activated cells, were able to suppress T cell proliferation approximately 50% compared to T cell 
treated with Concavalin A only. However, the degree of inhibition of T cell proliferation was not 
altered by MSC activation. Noteworthy, this effect required cell-cell contact since the assay using 
MSC-CMs failed to suppress the proliferation (data not shown).  
Additionally, MSC-CMs showed an inability to inhibit macrophage activation since there 
were no differences in MHC II expression and cytokines productions from LPS-activated 
macrophages despite treated with MSC-CMs (Figure 4.4B, C). We also observed the slightly 
reduced TNF-a production when activated macrophages were incubated with unstimulated MSC-
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CM (p = 0.063; Figure 4.4C). However, no change was observed in IL-10 production by LPS-
activated macrophages incubated with MSC-CMs. 
     
4.4.4 Activated and resting MSCs drive macrophage polarization toward the alternative type (M2) 
     We investigated the effect of preactivated MSC-CMs on macrophage polarization. 
Macrophages incubated with MSC-CMs were stained for CD206 and iNOS. The expression of the 
markers (MFI) was analyzed using image analysis, and the M2/M1 ratio were calculated. The 
marker expression was shown in the graph either with standard polarization or ratio to 
unstimulated CM (Figure 4.5). In general, M2 macrophage has been described to upregulate 
CD206 and less iNOS production34. We observed that Ctrl-MSC-CM and activated MSC-CMs 
except for Poly(I:C) group influenced the macrophage polarization toward M2-like phenotype 
indicating as CD206hi, iNOSlo compared to standard (Figure 4.5A, B). However, Poly(I:C) 
stimulation affected the macrophage phenotype to become CD206int, iNOSlo. Comparing M2/M1 
ratio among CMs treatment group, control MSC-CM was superior to others in M2 macrophage 
polarization since a significant greater M2/M1 ratio (p < 0.001) was observed as shown in Figure 
4.5C. 
 
4.4.5 Activated and resting MSCs support fibroblast proliferation and migration  
 The effect of MSC-CMs on fibroblast proliferation was evaluated using the MTT assay. 
Treatment with MSC-CMs showed a significant cell proliferation compared to untreated fibroblast 
(p <0.001, Figure 4.6A). Comparing to unstimulated cells, the preactivation of MSC slightly 
increased proliferation of fibroblast; however, there was no statistical difference effect by 
preactivation.   
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     The migration of fibroblast cells corresponding to MSC-CMs was measured by a scratch 
assay. At 48 hours, all MSC-CMs group showed an increase of fibroblast migration compared to 
untreated fibroblast, and some wells with CMs treatments started the closure of the scratch gap. 
The percentage of relative wound width reducing over times was shown in Figure 4.6B and 
summary values at 48 hours were reported as following; Ctrl-MSC-CM; 62.25 ± 12.29%, IFN-g-
MSC-CM; 80.55±18.62%, TNF-a-MSC-CM; 76.4±13.63%, Poly(I:C)-MSC-CM; 75.61±10.62%, 
LPS-MSC-CM; 75.04±10.40%. Unstimulated and preactivated MSC-CMs showed the significant 
wound reduction compared to untreated fibroblast at 48 hours, and the effect of preactivated CMs 
became overt at 36 hours of incubation. The effect of resting MSC was comparable to preactivated 
MSC. We also found that TNF-a significantly reduced wound width compared to Ctrl-MSC-CM 
(p = 0.017) at 36 hours suggesting the superior effect on fibroblast migration induced by TNF-a 
activated MSCs.  
 At 36 and 48 hours, treatment with MSC-CMs showed a significant increase of wound 
confluence indicating greater cell confluence in the wound regions compared to untreated 
fibroblast (p <0.001, Figure 4.6C). However, when compared the efficacy among the CMs 
treatment group, there was not different between the activated CMs and unstimulated CM. At 48 
hours, the relative wound confluences were reported as following; Ctrl-MSC-CM; 69.63 ± 7.93%, 
IFN-g-MSC-CM; 75.64 ± 7.35%, TNF-a-MSC-CM; 73.91 ± 9.78%, Poly(I:C)-MSC-CM; 72.44 
± 8.52%, LPS-MSC-CM; 72.07 ± 6.39%. Interestingly, the effect of preactivated CMs including 
a group of IFN-g, TNF-a and LPS became overt earlier at 24 hours of incubation indicating more 
rapid effect than unstimulated CM. In addition, we also assessed the relative wound density; 




4.4.6 Effect of preactivation of MSC on the phenotype of synoviocytes and proliferation. 
 We investigated the effect of MSC-CMs on synoviocytes activities in term of phenotype 
and proliferation. Synoviocytes treated with MSC-CMs have noticeable changes of the phenotype 
by upregulation MHC II and PD-L1 compared to untreated synoviocytes (Figure 4.7A, B; left 
panel). Also, IFN-g-MSC-CM treated synoviocytes showed 1.5 times increasing number of cells 
expressing PD-L1 compared to unstimulated MSC-CM effect (p = 0.042, Figure 4.7B; right panel). 
Also, MSC-CMs stimulated significant proliferation of synoviocytes compared to untreated cells 
measured by MTT assay (Figure 4.7C); however, there was no different effect among different 




 MSC treatments are promising in regenerative medicine because of several advantageous 
features including multipotency, self-renewable, accessible, and practical for clinical application. 
However, treatment with conventional MSCs has been reported to have ineffective and variable 
outcomes35-37 possibly because injected MSCs encounter insufficient concentrations of 
proinflammatory cytokines for full activation, or because of a biased cytokine milieu in vivo. Thus, 
reactivation the MSCs with inflammatory cytokines and TLR agonists has the potential to augment 
the immunomodulatory effects of MSC and to enhance tissue regeneration following MSC 
injection.  Also, the overall effects of preconditioning with these stimuli are mostly unknown in 
canine MSCs. Therefore, we investigated the effect of pretreatment of canine MSCs with 
inflammatory cytokines and TLR agonists and compared their features and functions to that of 
resting canine MSCs.  
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 In our study, preactivation of MSCs with inflammatory cytokines and TLRs agonists had 
little effect on either the phenotype or function of the MSC.  Resting canine MSCs were found to 
have unique features and functions including, lack of MHC II and PD-L1 expression, absence of 
IL-10 and TNF-a production consistent with other studies38. In our study, exposure of MSCs to 
inflammatory stimuli for 1 hour17 only activated two detectable responses: upregulation of PD-L1 
expression (IFN-g activation) and secretion of IL-8 (Poly(I:C) activation). However, most of the 
other functional assays for MSCs; including suppress of T cell proliferation, inhibit of macrophage 
activation by LPS; showed the comparable results between primed MSCs and resting MSC (Figure 
4.4). These results are different than those published by other groups studying mouse and human 
MSC in which they have observed significant immunosuppressive activity in human20, 25 and 
murine MSCs19, 39. Additionally, in murine and human MSCs activation with TLR agonists (i.e., 
Poly(I:C) and CpG oligonucleotides) has been shown to induce a high level of cytokines such as 
IL-10, IL-6, MCP-120, 25. However, in dogs none of these stimuli activated the MSC (Figure 4.3). 
We included studies with mouse MSC to point out the differences between preactivation of dog 
MSC versus mouse MSC in Figure 4.8.  These pieces of evidence suggest the existence of a unique 
hypo-responsive state in canine MSC. 
MSCs also secrete factors that regulate macrophage function and their effects on 
suppressing inflammation and tissue remodeling.  In our studies, we observed that conditioned 
medium (CM) from dog MSC altered the phenotype of dog monocyte-derived macrophages 
(upregulating CD206 expression and downregulating iNOS expression) (see Fig 4.5).  However, 
CM from pre-activated dog MSC had no additional effect on the phenotype of dog macrophages 
when compared to CM from dog MSC that were not pre-activated.  Thus, in terms of MSC effects 
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on macrophage phenotype and function, dog MSC also appear hypo-responsive to inflammatory 
stimuli, relative to MSC from other species. 
Besides immunosuppressive activity, MSCs have been shown to influence tissue healing 
for support the treatment of chronic inflammatory disease including OA and IBD. In this study, 
we examined the effect of CMs rather than cell-cell contact because the therapeutic effect is 
believed to achieve by paracrine and soluble factors37 since the very rare number of MSCs was 
found at the target tissue 40, 41 (i.e., joint and gut mucosa). As shown in our study, MSC-CM 
increased cell viability and proliferation of the cells in the joint environment including fibroblast 
and synoviocytes although the comparable effect was observed among all treatments, rapid onset 
was observed specifically in preactivated CMs (Figure 4.6, 4.7).  However, as before there was no 
effect of MSC pre-activation on the secretion of factors that alter fibroblast proliferation or 
migration. 
 There may be several explanations for the hypo-responsiveness of dog MSC to activation.  
For one, our study investigated the effect of short time activation of canine MSCs by inflammatory 
stimuli. Dosage and period of activation have been postulated to mimic the physiological state 25 
of MSCs in vivo and has been documented to achieve the activation of MSCs leading to 
downstream action including the NF-kB activation20, 25. However, previous studies in other species 
of MSC demonstrated that 1 hour was sufficient time for activation.  Moreover, our results with 
dog MSC also showed that 1-hour exposure to inflammatory stimuli was sufficient for immune 
activation.  Thus, the length of time of pre-activation is unlikely to explain our findings.  Contrary 
to our findings, the significant increase of IL-6, IL-10 and immune cell migration by Poly(I:C) and 
LPS activation were reported in that human MSCs studies20, 25, 42. These pieces of evidence 
suggested the interspecies variability of TLR response32 leading to a hypo-responsive feature of 
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canine MSCs. It should be noted that although there was a consistency effect in unique high IL-8 
observed in Poly(I:C) activation, we did observe donor variability influencing these patterns 
suggesting the different TLR activity in a different donor. However, very limited data regarding 
preactivated MSCs in canine species as well as no report of a clinical trial using the preactivated 
MSCs have been documented so far. Thus, more studies regarding alteration of features and 
function of preconditioning MSCs in dog are required. Also, further investigation on optimal 





 Preactivation of canine MSCs by inflammatory cytokines and TLR agonists exerts little 
effect on either phenotype or function.  These findings suggest that dog MSC are hypo-responsive 
to inflammatory stimuli, and provide little justification for using pre-activation as a strategy to 
improve the effectiveness of dog MSC in clinical studies.  Further studies are required to better 





Figure 4.1 Phenotypic evaluation of MSCs in response to the inflammatory cytokines and 
TLRs. Dot plot depicted the expression of surface markers; PD-L1, MHC II, CD 90, and CD73 
(one marker per row). In same row, the % of positive cells, Ratio of % positive cells to resting 
MSCs, and Ratio of MFI to resting MSCs were shown respectively. The statistics reported as 
mean, statistical differences were calculated using Kruskal-Wallis with Dunn’s multiple 
comparison (*p ≤ .05, **p ≤ .01, ***p ≤ .001). Abbreviations: PD-L1, Programed death-ligand 1; 
































































































































































































































































































































































































































































































Figure 4.2 IFN-g activation on MSCs; Dose-time course study. MSCs were incubated with 
multiple dose of IFN-g and cells were harvested on different incubation time to measure the 
expression of PD-L1 and MHC II. Bar graph depicted time course study of (A) PD-L1 and (B) 






Figure 4.3 Cytokines production of preactivated MSCs. Dot plot depicted the concentration of 
cytokines (pg/ml) and the ratio to control MSCs. The statistics reported as mean ± SD, statistical 
differences were calculated using Kruskal-Wallis with Dunn’s multiple comparison (*p ≤ .05, **p 
≤ .01, ***p ≤ .001). Abbreviations: IL-6, Interleukin 6; IL-8, Interleukin 8; IL-1B, Interleukin 1 












































































































































































































































































































































Figure 4.4 Impact of MSC activation on T cell and macrophage activity. (A) Dot plot depicted 
the suppression of T cell proliferation in response to precondition stimuli; (Left) % suppression 
and (Right) MFI EDU. (B) Bar graph depicted the expression of MHC II on LPS-activated 
macrophage incubated with activated MSC-CMs; (Left) % of positive cells and (Right) MFI of 
MHC II. (C) Bar graph depicted level of cytokines released by LPS-activated macrophage with 
preconditioning MSC-CMs; (Left) IL-10 and (Right) TNF-a. The statistics reported as mean ± SD, 
statistical differences were calculated using One-way ANOVA with Tukey’s adjustment (*p ≤ .05, 
**p ≤ .01, ***p ≤ .001). Abbreviations: MHC II, major histocompatibility class II; IL-10, 
Interleukin 10; IL-8, Interleukin 8; TNF, tumor necrotic factor; MSC, mesenchymal stem cell; 

















































































































































































































































































Figure 4.5 Macrophage polarization by preactivated MSC-CMs. (A, B) Dot plot showed the 
expression of surface markers of macrophage (A) CD206; (Left) MFI and (Right) Ratio of MFI to 
unstimulated MSC-CMs, (B) iNOS; (Left) MFI and (Right) Ratio of MFI to unstimulated MSC-
CMs. (C) Dot plot depicted the ratio of CD206/iNOS cells (M2/M1), and M2/M1 Ratio compared 
to Ctrl-CMs (Right). The statistics reported as mean ± SD, statistical differences were calculated 




































































































































































































































Kruskal-Wallis with Dunn’s multiple comparison (*p ≤ .05, **p ≤ .01, ***p ≤ .001, ****p ≤ 
.0001). Abbreviations:  Mφ, macrophage; MFI, mean fluorescence intensity; CD, cluster of 
differentiation, iNOS, induced nitric oxide synthase.  
 
 
Figure 4.6 MSC-CMs support fibroblast proliferation and migration. (A) Bar graph showed 
the fibroblast proliferation in response to preconditioned MSC-CMs measured by MTT assay, (B) 
% wound width and (C) % relative wound confluence over times.  The statistics reported as mean 
± SD, statistical differences were calculated using Two-way ANOVA with Tukey’s adjustment 



















































Figure 4.7 MSC-CMs effect on phenotype of synoviocytes and proliferation. Bar graph 
showed the expression of surface markers; (A) MHC II, (B) PD-L1 of synoviocytes incubated with 
MSC-CMs for 2 days. Dot plot depicted the ratio compared to untreated synoviocytes; (A) MHC 
II expression, (B) ratio of % PD-L1+ve cells to untreated cells. The statistics reported as mean ± 
SD, statistical differences were calculated using (A,B; Left panel, and C) One-way ANOVA with 
Tukey’s adjustment, and (A,B; Right panel) Kruskal-Wallis with Dunn’s multiple comparison (*p 



















































































































































Figure 4.8 Cytokines production differences between mouse and canine MSC. Dot plot 
depicted cytokine production ratio to control MSCs. Activation of mouse MSC with the same 
dosage and time of activation showed more response to activation by Poly(I:C) and LPS compare 
to canine MSC. The statistics reported as mean ± SD, statistical differences were calculated using 
Kruskal-Wallis with Dunn’s multiple comparison (*p ≤ .05, **p ≤ .01, ***p ≤ .001). 
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CHAPTER 5: CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
5.1 Significance of Work 
 
 The goal of the research presented in this dissertation was to comprehensively investigate 
the impact of activated and resting MSCs on immune responses, cells regeneration and gut 
microbiome for treatment of IBD with a specific emphasis on gaining an improved understanding 
of the immune responses to the gut bacteria in dogs with IBD. IBD in dogs represent a significant 
chronic inflammatory condition affecting the GI in humans known as Crohn’s disease and 
Ulcerative Colitis. The disease potential affects 100-200 per 100,000 people in North America and 
it is emerging to the other parts of the world including Asia1. Not only humans, IBD dogs also 
suffer from this chronic disease and most of them experienced impaired quality of life due to the 
complication and adverse effect from medical and surgical treatment. Thus, the MSCs is promising 
to be an effective treatment with safe and less side-effect for IBD treatment. Additionally, the 
primary features of IBD in dogs mostly resemble those in humans 2, 3, including unknown cause 4-
6, high genetic sequence similarity 7 and pathogenesis 8, as well as the need for clinical 
intervention9, 10. Thus, spontaneous IBD in dog is considered a potential model for study, with the 
potential for extrapolation to human IBD.  
This work was the comprehensive studies that integrated the works starting from a basic 
science (i.e., cell cultures) to laboratory animal model (i.e., mouse model of colitis) and the 
knowledge obtained from this work eventually have a potential to apply on clinic either veterinary 
or human medicine. Hopefully, some aspects of this research could impact on the current treatment 
of IBD and potential draw the further investigations in the future. In chapter 2, we investigated the 
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humoral immune response against gut bacteria in dogs with IBD. In this part, we determined 
whether dogs with IBD have more IgG-binding bacteria and the potential consequence to trigger 
GI inflammation. Also, Chapter 3, we investigate the effectiveness of using iMSCs and 
conventional adipose-derived MSCs for the treatment of IBD in a mouse model of DSS-induced 
colitis. In chapter 4, we investigate the response of canine MSCs to inflammatory stimuli and their 
interactions with immune cells and potential regenerative effect on cells from joint 
microenvironment. This would be the way to improve the efficacy of conventional MSCs 
treatment.  Based on the collective finding of this work we can conclude that treatment with MSCs 
is a promising treatment for IBD since they have shown the remarkable properties in anti-
inflammation, tissue regeneration as well as microbiome restoration.  
By investigating an immune response to gut bacteria in chapter 2, we also conclude that 
the mucosal antibody binding to commensal gut bacteria was substantially greater in dog with IBD 
compared to a healthy, and the immune targeted particular bacteria and triggered the pro-
inflammatory response. As IBD caused by dysregulation of immune and the over response to their 
gut bacteria as we found from chapter 2.  
Based on the findings from chapter 3, we conclude that MSCs are effective for IBD 
treatment and we support the use of either iMSCs or adMSCs since they were mostly equivalent. 
However, conventional MSCs has known to have several limitations including the variable 
treatment effect caused by un-uniform cell source and loss of potency by senescence. Thus, iMSCs 
is probably the better choice, however, further study regarding safety need to be done.  
Also, we examine the impact of precondition MSCs compared to resting MSCs in chapter 
4. We conclude that preactivation of MSCs potentially induced a few changes of phenotypes and 
functions and most of the immune response were comparable to a resting MSCs. Further 
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investigation on optimal activation to achieve an effective MSCs remains a challenge and would 
be of interest for clinical application. 
  
5.2 Future Directions 
  
 Based on the findings and our conclusion, iMSC is effective in treatment of IBD and has 
advantageous properties for the convenient use and potential for clinical application including 
exceptional expandability and easy quality control. However, several essential drawbacks must be 
concerned including safety, genetic stability, consistency of phenotype and function. Also, iMSCs 
is novel and has been recently developed. There is the limited resources and small number of back 
up evidence. Most of the studies have been reported from the side of pure science evidence, very 
few studies was conducted in animal model or safety study11 and no clinical trial has been 
documented. Thus, future studies in animal model including spontaneous IBD in dog or large scale 
of clinical trial for long-term follow-up to determine iMSC safety and efficacy is required before 
clinical translation.      
 Our work also supports the use of conventional MSCs for treatment of inflammatory 
diseases and allogeneic source is convenient, safe and practical. However, the previous studies 
have reported inconsistent outcomes of allogenic MSC treatment 12, 13, suggesting from the 
different phenotype, function, uniformity and cell quality that MSC may be altered in long-term 
cell culture 12, 14, 15, thereby leading to a reduced therapeutic outcome 16, 17. Therefore, we 
investigated the effect of preconditioned MSCs in vitro (chapter 4). Although the effect of 
preactivated MSC was barely enhanced by an activation contrary to the findings from other 
species. This low response may be caused by interspecies difference in TLRs response. Study 
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focused on the combination of stimuli, variety of dose and time for activation would be useful and 
potential to develop the standard protocol for precondition the MSCs. The same setting can apply 
to test on iMSC as well. Therefore, further study for optimal activation to obtain suitable 
phenotypes and functions corresponding to specific disease remains a challenge and is still a need.  
 Although this study has shown the effective of MSCs in treatment of mouse model of 
colitis. The similar outcome when apply the treatment to larger animal or in clinical trial cannot 
be ensured. For example, several studies have reported the failure of MSCs engraftment although 
the promising result were obtained during the experiment in animal model13, 18. Therefore, clinical 
trial study in larger population for investigate the efficacy and safety of MSCs in IBD treatment is 
ultimately required. Also, various trial designs may be useful to evaluate the optimal method or 
standard protocol for the maximum therapeutic efficacy.  
 The MSC therapeutic effect in IBD does not depend on their full engraftment but mainly 
on the secretory mediators. Many assays included in this study, we have been using the condition 
media/secretome of MSCs to induce the response of immunomodulation and cell regeneration. We 
also found that secretome is likely effective as cellular therapy but more convenient, easy to use 
and long-term store. However, concerns of the duration of action and cost of production were 
described in previous studies. The study to investigate the use of MSC secretome and their effect 
would be developed.   
 Our findings from chapter 2 indicated that a bacterial flow cytometric IgG assay using fecal 
samples provided significant sensitivity and specificity to distinguish dogs with IBD from healthy 
dogs. These outcomes must be proven in larger population in dogs with IBD and compared to 
animals with other causes for GI dysfunction, including viral infection, and infections with GI 
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parasites. Furthermore, the analysis of the serial samples at a later stage after treatment at the 
various follow-up time points could also be beneficial. 
 Overall, we finally need to develop our comprehensive understanding regarding the 
immunopathogenesis of the IBD and how the MSCs effect in that process. Also, thoroughly know 
the most parts of pro and con of MSCs would be essential. Therefore, there are the great 
opportunities for continued study in these areas, and the studies described in this dissertation 
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